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INTRODUCTION 
“Analytical  Chemistry is  what  analytical  chemist  do”.  Analytical  Chemistry is 
often described as the area of chemistry responsible for characterizing the composition 
of matter, both Qualitatively (what is present) and Quantitatively (how much is present).
Analytical techniques hold the key to the design development standardization and 
quality control of medical products. They are equally important in pharmacokinetics and 
in  drug  metabolism  studies  both  of  which  are  fundamental  to  the  assessment  of 
bioavailability and the duration of clinical response.
Analytical  instrumentation  plays  an  important  role  in  the  production  and 
evaluation of new products and in the production of consumers and the environment.
Chemical analysis is generally applied in two areas.
• Quantitative analysis
• Qualitative analysis
Quantitative analysis:
The  realm  of  quantitative  analysis  is  to  determine  how  much  of  each  of 
component or of a specified component is present in the sample.
Qualitative analysis:
The realm of qualitative analysis is  to determine the component present  if  the 
sample or perhaps confirming its presence (or) absence in the sample.
SPECTROSCOPY
It is the measurement and interpretation of electromagnetic radiations absorbed or 
emitted when the molecules or atoms or ions of the sample undergo transition from one 
energy state (ground state) to another (excited state).
UV- Visible spectroscopy
It involves the measurement of amount of UV radiation absorbed by a substance 
in  the  solution.  The  wavelength  between  190-390  nm  (practically  200-400  nm)  is 
considered to be UV radiations / region.
Wavelength is defined as the distance between any two consecutive parts of the 
wave whose vibrations are in phase. For example from the crest of one wave to that of 
the next. Its symbol is λ. Coloured compounds absorb in visible range i.e. 400 – 800 nm. 
The wavelength at which maximum absorbance takes place is called as λmax.
The assay of the absorbing substance can be carried out by using:
• Standard absorbtivity value
• Use of calibration graph
• Single point standardization
• Standard absorbtivity value
This  procedure  is  adopted  by  official  compendia  for  the  stable  substance  that  have 
reasonably broad absorption bands and which are practically unaffected by variation of 
instrumental  parameters.  The  use  of  standard  A(1% 1cm)  value  avoids  the  need  to 
prepare  a  standard  solution  of  the  reference  substance  in  order  to  determine  its 
absorpitivity.
Use of calibration graph:
 In this procedure the absorbance of a number typically (4 – 6) of standard solution 
of  the  reference  substance  at  concentrations  encompassing  sample  concentration  are 
measured and the calibration graph is constructed.
The concentration of the analide in the sample solution is read from the graph as a 
concentration corresponding to the absorbance of the solution.
Single point standardization
This procedure involves the measurement of the absorbance of a sample solution 
and of a standard solution of the reference substance. The standard and sample solutions 
are  prepared  in  the  reference  manner.  Ideally  of  the  concentration  of  the  standard 
solution should be close to that sample solution. The concentration of the substance in 
the sample is calculated using
C test =   A text x C standard
                 _____________
 A standard                        
Where C test  and C standard  are the concentrations in the sample and standard solution 
A text and A standard  are the absorbance of the sample and standard solution respectively. 
The use of UV and visible spectroscopy for quantitative analysis employs the method of 
comparing  the  absorbance  of  standards  and  samples  at  a  selected  wavelength.  The 
analysis of mixtures of two or more complements is facilitated by activity of absorbance. 
Other applications include measurement of absorption of complexes to establish their 
composition  of  all  chromogenic  compounds  are  not  suitable  for  quantitative 
measurement  i.e.,  the  choice  of  the  system  and  procedure  depends  largely  on  the 
chemistry of the species to be determined.
Assay of substances in multi component samples they are:
• Simultaneous Equation method
• Absorbance ratio method
• Derivative spectroscopy method
• Chemical derivatisation method
• Multi – component mode of analysis
Simultaneous Equation method:
If a sample contains two absorbing drugs (X and Y) each of which absorbs at the 
λmax of the other. It may be possible to determine the quantity of both drugs by the 
technique of simultaneous equation (or) Vierodt’s method. Criteria  for  obtaining 
maximum precision based upon absorbance ratios have been suggested that place limits 
on the relative concentrations of the component of the mixture.
A2 ⁄ A1                  and ay1 / ay2
             _______    ________
ax2 ⁄ ax1 A2 ⁄ A1
Where
ax1, ax2               = Absorptivities of X at λ1 and λ2
ay1, ay2               = Absorptivities of Y at λ1 and λ2
A1, A2                            = Absorbances of the diluted 
  Sample at λ1 and λ2
The ratio should lie outside the range f 0.1 – 2.0 for the precise determination of 
(Y and X) two drugs respectively.
These  criteria  are  satisfactory  only  when  the  λmax   of  the  two  components  is 
reasonable dissimilar. The additional criteria includes that the two additional criteria do 
not interact chemically thereby negating the initial assumption that he total absorbance is 
the sum of the individual absorbance’s.
Derivative spectroscopic method:
This method involves the conversion of normal spectrum to its first, second or 
higher derivative spectrum the transformations that occur in the derivation spectra are 
understood by reference to an ideal absorption band. For the purpose of spectral analysis 
to relate chemical structure to electronic transition and for analysis situations in which 
mixtures contribute interfering absorption. A method of manipulating the spectral data 
called derivative spectroscopy was developed. 
In this technique spectra are obtained by plotting the first or higher derivation of 
absorbance or transmittance with respect to wavelength versus wavelength. Often these 
plots  reverse  spectral  details  which  is  lost  in  an  ordinary  spectrum.  In  addition 
concentration  measurement  of  an  analyte  in  the  presence  of  their  interference  can 
something be made easily or more accurately.
Chemical Derivatisation Method:
Indirect spectrophotometic assays are based on the conversion of the analyte by a 
chemical reagent to a derivative that has different spectral properties.
This method is employed:
If the analyte absorbs weekly in the uv-region, a more sensitive method of assay is 
obtained by converting the substance to a derivative with a more intensely absorbing 
chromophore.
• The interference from irrelevant absorption may be avoided by converting 
the  analyte  to  its  derivative  which  absorbs  in  the  visible  region  where 
irrelevant absorption is negligible.
•      Indirect  Spectrophotometric  procedure  is  also  used  to  improve  the 
selectivity of the assay of an ultra violet absorbing substance in a sample that 
contains other UV-absorbing components.
CHROMATOGRAPHY 
Modern  pharmaceutical  formulations  are  complex  mixtures  containing  one  or 
more therapeutically active ingredients.,  to a number of inert  materials like diluents, 
disintegrants, colourants and flavours in order to ensure quality and stability of the final 
product, the pharmaceutical analyst must be able to separate the mixtures into individual 
components  prior  to  quantitative  analysis.  Amongst  the  most  powerful  techniques 
available to the analyst for the separation of these mixtures, a group of highly efficient 
methods which are collectively called as chromatography. It’s group of technique which 
works  on  the  principle  of  separation  of  components  of  a  mixture  into  individual 
components,  depending  on  their  affinities  for  the  solutes  between  two  immiscible 
phases. One of the phases is affixed bed of large surface area, while the other is a fluid, 
which moves through the surface of the fixed phase. The fixed phase is called stationary 
phase  and  the  other  is  termed  as  the  mobile  phase.  Depending  on  the  type  of 
chromatography  employed  the  mobile  phase  may  be  a  pure  liquid  or  a  mixture  of 
solutions (eg.buffer) or it may be gas (pure or homogenous mixture).
Classification of chromatography:
It can be classified according to the nature of the stationary and mobile phases.
The different types of chromatography are
• Adsorption chromatography
• Partition chromatography
• Ion exchange chromatography
• Size exclusion or gel permeation chromatography
The modern instrumental techniques GLC, HPLC and HPTLC provide excellent 
separation  and  allow accurate  assay  of  very  low concentrations  of  wide  variety  of 
substance in complex mixtures.
High Performance liquid chromatography:
HPLC is one among most useful tools available for quantitative analysis. Reverse 
phase  chromatography  refers  to  the  use  of  a  polar  mobile  phase  with  a  non  polar 
stationary phase in contract to normal phase being employed with a non polar mobile 
phase.
Liquid  chromatography  is  based  upon  the  phenomenon  that,  under  the  same 
conditions, each component in a mixture interacts with its environment differently from 
other components. Since HPLC is basically a separating technique analysis. It is always 
used in conjunction with another analytical tool for quantitative and qualitative analysis. 
The mode of operation of this system is isocratic. i.e. one particular solvent or mixture is 
pumped throughout the analysis for some determinations the solvent composition may 
be altered gradually to give gradient elution.
The rate of distribution of drugs between stationary and mobile phase is controlled 
by diffusion process, if diffusion is minimized, a faster and effective separation can be 
achieved.  The  techniques  of  high  performance  liquid  chromatography  are  so  called 
because  of  its  improved  performance  when  compared  to  classical  column 
chromatography. Advances in column technology high pressure pumping system and 
sensitive detectors  have transformed liquid column chromatography into high speed, 
efficient, accurate and highly resolved method of separation.
Modes of separation:
In normal phase mode the stationary phase (e.g. silica gel) is polar in nature and 
the mobile phase is non-polar. In this technique non-polar compounds travel faster and 
are eluted first. This is because less affinity between solute and stationary phase. Polar 
compounds are retained for longer time in the column because more affinity towards 
stationary  phase  and  takes  more  time  to  be  eluted  form  the  column.  This  is  not 
advantageous in pharmaceutical applications since most of the drug molecules are polar 
in nature and takes longer time to be eluted and detected. Hence this technique is not 
widely used in pharmacy.
Importance of polarity in HPLC:
Polarity is a term that is used in chromatography as an index of the ability of 
compounds to interact with one another. It is applied very freely to solutes. Stationary 
and mobile phase HPLC, the eluting power or solvent strength of the mobile phase is 
mainly determined by its polarity. If the polarities of stationary phase and the mobile 
phase are similar, it is likely that the interactions of solute with each phase may also be 
similar, resulting in poor separation. Retention of solutes is usually altered by changing 
the polarity of the mobile phase.
Packing materials and mobile phases:
Many of  the  packing materials  used  in  HPLC are  based on materials  used in 
classical  column  chromatography.  The  commonly  used  packing  materials  and  their 
associated solvent systems in each of the chromatographic modes are
1) Partition HPLC
2) Adsorption HPLC
Adsorption HPLC:
Adsorbents  used  in  classical  column  chromatography,  unmodified  silica  has 
proved  to  be  the  most  widely  used  in  HPLC.  The  functional  group responsible  for 
adsorption is  the silanol  (Si-OH) group which interacts  with  the sample solutes  by 
hydrogen bonding.  There is  therefore  increasing  retention of  solutes  with increasing 
solute polarity. Alumina is used as an adsorbent less frequently than silica, although for 
some separations in particular of aromatic substances and of structural isomers, greater 
selectivity is obtained with alumina.
Partition HPLC:
Packing materials based on silica are also used in partition chromatography. Early 
applications of partition HPLC involved coating the silica with a polar liquid stationary 
phase. Eg. Ethane – 1, 2-diol. Such packing materials have now been replaced by silica 
to which polar phases are chemically bonded. Example, 
Si – (CH2)3 – O- CH2 – CH - CH2
                                                I        I
        OH    OH
Eg. LiChrosorb Diol
Si – (CH2)3 – CN                e.g. Q Bond pak CN
Si – (CH2)3 – NH2              e.g. Polygosil NH2
In reversed – phase partition  HPLC the relative polarities of the stationary and 
mobile phase are the opposite to those in normal phase HPLC, i.e., the stationary phase 
is less polar than the mobile phase, and consequently the solutes are eluted in the order 
of their decreasing polarities. The stationary phase is silica, chemically bonded through a 
siloxame (si-o-si-o) linkage to a low polar functional group. These phases are prepared 
by treating the surface silanol groups of silica with an organochlorosilane reagent 
CH3                                                       CH3
   I                                        I
                            -SI - OH+ CI- SI- R ---->     - SI – O –SI –R +HCL
   I                                        I
CH3                                                       CH3
   
Where R              = C6H13   (Hexyl)
   C8H17   (Octyl)
                               C18H37  (Octadecyl)
Untreated  silanol  groups  may  be  ‘capped’  by  treatment  with 
trimethlchlorosilane to eliminate adsorption effects. The mobile phase in reversed- phase 
HPLC  generally  comprises  water  and  a  less  polar  organic  solvent  modifier.  e.g. 
methonal  or  acetonitrile.  Separations  in  these  systems  are  considered  to  be  due  to 
different degrees of hydrophobicity of the solutes. The less polar solutes partitioning to a 
greater extent into the non-polar stationary phase and consequently being retained on the 
column longer than the more polar solutes. The rate of elution of the components is 
controlled by the polarity of the organic modifier and its proportion in the mobile phase. 
The  rate  of  elution  is  increased  by  reducing  the  polarity,  e.g.  by  increasing  the 
proportion  of  the  organic  solvent  or  by  using  acetonitrile  instead  of  methanol.  The 
simple alteration of the composition of the mobile phase or of flow rate allows the rate 
of elution of the solutes to be adjusted to an optimum value and permits the separation of 
a wide range of chemical types.
Detectors:
The detection of the separated components in the eluate from the column is based 
upon the bulk property or the solute property of the individual components. The most 
commonly used detectors in the HPLC are:
I. Photometric detectors:
These normally operate in the ultraviolet  region of spectrum and are the most 
extensively used detectors in pharmaceutical analysis. They are of five principal types :
• Single wavelength detectors
• Multi-wavelength detectors
• Variable wavelength detectors
• Programmable detectors
• Diode array detectors
ii. Fluorescence detectors:
These  are  essentially  filter  fluorimeters  or  spectrofluorimeters  equipped  with 
grating  monochromators  and  micro  flow  cells.  Their  sensitivity  depends  on  the 
fluorescence properties of the components in the elute.
iii. Refractive index detectors:
These  are  differential  refractometers  which  respond to  the change in  the  bulk 
property of the refractive index of the solution of the component in the mobile solvent 
system. The sensitivity of the refractive index detector is much less than that of specific 
solute property detectors.
iv. Electrochemical detectors :
These are based on standard electrochemical  principles involving amperometry 
voltammetry and polarography. These detectors are very sensitive for substances that are 
eletroactive.
Validation 8, 9,10 
Validation  means  assessment  of  validity  or  action  of  proving  effectiveness. 
Method validation is the process of proving that in analytical method is acceptable for its 
intended  purpose.  For  pharamaceutical  methods  guidelines  from  the  united  states 
pharmacopeia (USP), international conference on harmonization (ICH) and the food and 
drug administration (FDA) provide a frame work for performing such validations
Parameters used for assay validation
The validation of the assay procedure was carried out as per ICH guidelines using 
the following parameters.
Specificity:
Specificity  is  the ability  to  asses unequivocally  the analyte  in the presence of 
components which may be expected to be present, lack of specificity of an individual 
analytical procedure may be compensated by other supporting analytical procedures. For 
the  chromatographic  methods  developing  a  separation  involves  demonstrating 
specificity, which is the ability of the method to accurately measure the analyte response 
in the presence of all potential sample components. The response of the analyte in test 
mixtures  containing  the  analyte  and  all  potential  sample  components  (placebo 
formulation,  process  impurities,  etc.)  is  compared  with  the  response  of  a  solution 
containing only the analyte. Specificity criteria for an assay method is that the analyte 
peak will have baseline chromatographic resolution of at least 1.5 from all other sample 
components. If this cannot be achieved the unresolved components at there maximum 
expected level will not affect the final assay result by more than 0.5%
Linearity :
Linearity of an analytical procedure is its ability ( within a given range) to 
obtained test results, which are directly proportional to the concentration (amount) of 
analyte in the sample. For assay methods, this study is generally performed by preparing 
standard  solutions  at  five  concentration  levels.  Five  levels  are  required  to  allow 
detection of curvature in the plotted data acceptability of linearity data is often judged by 
examining   the correlation and y – intercept of the linear regression line for the response 
versus concentration plot. A correlation coefficient of >0.999 is generally considered as 
evidence of acceptable fit of the data to the regression line. The y- intercept should be 
less than a few percent of the response obtained for the analyte at the target level.
Accuracy:
The  accuracy  of  an  analytical  procedure  expresses  the  closeness  of 
agreement between the value which is accepted either as a conventional true value or an 
accepted reference value and the value found. The accuracy of a method is the closeness 
of the measured value to the true value for the sample. Accuracy is usually determined 
in one of four ways.
1.  Accuracy can be assessed by analyzing a sample of known      concentration and 
comparing the measured value to the true value.
2. To compare test results from the new method with results from an     existing alternate 
method that is known to be accurate.
3. To most widely used recovery study, is performed by spiking analyte  
in blank matrices. For assay methods, spiked samples are prepared     in triplicate at 
three levels over a range of 50-150% of the target     concentration.  
4.  The technique of standard additions, which can also be used to      determine recovery 
of spiked analyte. This approach is used if it is      not possible to prepare a blank sample 
matrix without the presence      of the analyte.  Accuracy criteria for an assay method is 
that the mean recovery will be 100+2% at each concentration over the range of 80-120% 
of the target concentration.
Range:
 Range  of  analytical  procedure  is  the  interval  between  the  upper  and  lower 
concentration amounts of analyte in the sample including these concentration for which 
it has been demonstrated that the analytical procedure has a suitable level of precision, 
accuracy  and  linearity.  The  range  is  determined  using  data  from  the  linearity  and 
accuracy studies. Range criteria for an assay method is that the acceptable range will be 
defined as the concentration interval over which linearity and accuracy are obtained per 
previously discussed criteria and that yields a precision of 3% RSD.
Precision: 
The  precision  of  an  analytical  procedure  express  the  closeness  of  agreement 
between  a  series  of  measurements  obtained  from  multiple  sampling  of  the  same 
homogenous  sample  under  the  prescribed  conditions.  Precision  of  an  analytical 
procedure is usually expressed the variance, standard deviation or coefficient of variance 
of a series of measurements. The first type of precision study is instrument precision or 
injection repeatability. A minimum of 10 injections of one sample solution is made to 
test the performance of the chromatographic instrument. The second type is repeatability 
or intra-assay precision. Intra- assay precision data are obtained on one day. Aliquots of 
a homogenous sample, each of which has been independently prepared according to the 
method procedure from these precision studies, the sample preparation procedure the 
number of replicate samples to be prepared, and the number of injections required for 
each sample in the final method is that the instrument precision (RSD) will be 1% and 
the intra assay precision will be 2%
Detection limit
The detection limit of an individual analyte procedure is the lowest amount of 
analyte in a sample which can be detected but not necessarily qualitated as an exact 
value. Detection limit based on the standard derivation of the response and the slope.
Detection limit (or) limit of detection may be expressed as, 
DL =     3.3 xσ
                           m
                      
Where 
σ  =  standard deviation of the response 
m  = slope of the calibration curve ( of the analyte )
Quantitation limit:
The quantitation of an analytical procedure is the lowest amount of analyte in a 
sample, which can be quantitatively determined with suitable precision and accuracy.
Quantitation limit based on the standard deviation of the response and the slope. It 
can be expressed as,
QL =     10x σ
       m
Where
         σ  =  standard deviation of the response 
        m  = slope of the calibration curve ( of the analyte )
Ruggedness:
The ruggedness of an analytical method is the degree of reproducibility of test 
result  obtained,  the  analysis  of  conditions  such  as  different  laboratories,  different 
analysis  using  different  instrument,  on  different  days.  Different  source  of  reagent, 
elapsed  assay  times,  assay  temperature  conditions.  Ruggedness  is  a  measure  of 
reproducibility of test result under the variation in conditions normally expected from 
analyst to analyst. The criteria of the ruggedness is the RSD should be not more than 
2%.
Robustness:
The robustness of a method is its ability to remain unaffected by small changes in 
parameter  such  as  percent  organic  content  and  pH of  the  mobile  phase,  buffer 
concentration and temperature and injection volume. These method parameters may be 
evaluated one factor at a time or simultaneously as part of a factorial experiment. The 
criteria for robustness is the RSD should be not more than 2%.
System suitability testing:
System suitability testing is an integral part  of many analytical procedures the 
tests are based on the concept that the equipment, electronics, analytical operation and 
samples to  be  analyzed constitute  an integral  system that  can  be evaluated as  such. 
Typically  the  process  involves  making  five  injections  of  a  standard  solution  and 
evaluating  several  chromatographic  parameters  such  as  resolution,  area  % 
reproducibility, number of theoretical plates and tailing factor.
Retention time: ( Rt )
This  is  the  time  of  emergence  of  the  peak  maximum  of  a  compound  after 
injection.
Retention volume: (RV)
The volume of mobile phase requires to elute one half of the compound from the 
column as indicated by the peak maximum and is given by   Rv = R t    x       flow rate
Asymmetry factor ( or ) tailing factor ( T )
T     =        Y x 
                             2A
where,
Y X     =   the width of the peak at one twentieth of the peak height.
A       =   the distance between the perpendicular dropped from the peak  
              Maximum and the leading edge of the peak at one twentieth of the   
              peak height.
The value lies between 0.95 to 1.05.
Number of theoretical plates (N)
N  =  5.54 x  ( Rt  )2
                               Wh/2
   
The  assessment  of  performance  of  efficiency  of  a  column  is  in  terms  of  the 
number of theoretical plates.
R t    =     retention time
W    =      width of peak at half height
Resolution ( R): 
R =     2 (Rt2- Rt1)
                            ------------------
    Wt1+ Wt2  
This gives the resolution between the measured peaks on the chromatogram.
Where
Rt1 and Rt2  = retention time of two component.
Wt1 and Wt2  = the respective peak width. Resolution between                
                                 measured peaks on the chromatogram must be > 1
STATISTICAL PARAMETERS
Statistics consists of a set of methods and rules for organizing and interpreting 
observations.
Lineanrity coefficient ( )ү
         _       _
∑ (X-X) (Y-Y)
                                                  =  ------------------Ү
        _       _
∑ (X-X)2 (Y-Y)2
Slope (m)                                       _       _
∑ (X-X) (Y-Y)
                                              m    =  ------------------
              _       
     ∑ (X-X)2 
Standard deviation (σ)                        _       
     ∑ (X-X)2 
                                           (σ)       =  ------------------
        n -1  
R.S.D (%)  = S.D 
                                                                    ----    X 100    
           X
Where
∑ = Sum of observation
X = Mean of arithmetic average (∑x/n)
X = Individual observed value.
x-x = Deviation of a value from the mean
N = Number of observation
R.S.D = Relative standard deviation
Now in  advanced  type  of  analytical  instrument  the  number  of  theoretical  plate  per 
column/ meter and tailing factor will be displayed automatically.
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Validation for Release to laboratory         
“Validation does not make a method good or efficient: it merely demonstrates that 
an analytical method performs in accordance with the claims made for it”.
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dextromethorphan HBr and drotaverine Hcl in their Pharmaceutical preparations. 
Using chromotrope 2B (C2B) and chromotrope 2R (C2R).  The method consists 
of extracting the formed ion-associates into chloroform in the case of pipazethate 
HCL  and  dextromethorphan  HBr  or  into  methylene  chloride  in  the  case  of 
drotaverine HCI.  The ion-associates exhibit absorption maxima at 528, 540 and 
532 nm with C2B and at 526, 517 and 522 nm with C2R for pipazethate HCI, 
dextromethorphan HBr and drotaverine HCI, respectively.  The calibration curves 
resulting  from the  measurements  of  absorbance-concentration  relations  (at  the 
optimum  reaction  conditions)  of  the  extracted  ion-pairs  are  linear  over  the 
concentration  range  4.36-52.32  microg  mL  (-1)  for  pipazethate,  3.7-48.15  , 
microg  mL(-1)  for  dextromethorphan  and  4.34-60.76  microg  mL(-1)  for 
drotaverine, respectively25.  
10. Metwally  FH,  et  al;  Determination  of  nifuroxazide  and  drotaverine 
hydrochloride  in  pharmaceutical  preparations  by  three  in  dependent  analytical 
method.  The first method was spectrophotometric, which allowed determination 
of 1 in the presence of II using a zero – order spectrum with an analytically useful 
maximum at 364.5 nm that obeyed Beer’s law over a concentration range of 2-10 
microg/mL with mean percentage recovery of 100.08+/- 0.61.  Determination of 
II in presence of I was obtained by second derivative spectrophotometry at 243.6 
which obeyed Beer’s law over a concentration range of  2-10 microg/mL with 
mean recovery of 99.82+/- 1.46%.  The second method was spectrodensitometry, 
with which both drugs were separated on a silica  gel  plate  using chloroform-
acetone-methanol-glacial  acetic  acid  (6+3+0.9+0.1)  as  the  mobile  phase  and 
untraviolet  (UV)  detection  at  365  nm  over  a  concentration  range  of  0.2-1 
microg/band for both drugs, with mean recoveries of 99.99+/- 0.15 and 100.00 +/- 
0.34% for  I  and II,  respectively.  The third method was reversed phase liquid 
chromatography using acetonitrile-water (40+60, v/v; adjusted to pH 2.55 with 
orthophosphoric  acid)  as  the  mobile  phase  and  pentoxifyline  as  the  internal 
standard  at  a  flow  rate  of  1  mU/min  UV  detection  at  285  nm  at  ambient 
temperature over a concentration range of 2-10 microg/mL for both drugs, with 
mean recoveries of 100.24+/- 1.51 and 100.08 +/- 0.78% for I and II, respectively 
26.
11. EI  –  saharty  ys  et  al;  studied  the  application  of  new  membrane  selective 
electrodes  for  the  determination  of  drotaverine  hydrochloride  in  tablets  and 
plasma27.
12. Daabees,  H.G. et  al;  carried out  the selective  Differential  spectrophotometric 
Methods  for  Determination  of  Niclosamide  and  Drotaverine  hydrochloride. 
Differential  (DEL TAA) second derivative  (DELTAD2)  AND third  derivative 
(DELTAD3)  differential  untraviolet  spectrophotometric  methods  have  been 
presented for  the quantitation of  niclosamide and drotaverine hydrochloride in 
pure  forms  and  in  their  pharmaceutical  formulations.   For  niclosamide,  the 
method is based on measuring DELTADELTA A, DELTA DEL TAD2, DELTA 
DELTAD3 of  niclosamide  in  alkaline  solutions  against  heir  neutral  ethanolic 
solutions as blanks.  For drotaverine hydrochloride,  the acidic solutions of the 
drug are measured against their alkaline solutions as blanks28.
13. Fadia H Metwally et al; studied the application of derivative, derivative ratio and 
multivariate spectral analysis and thin layer chromatography – densitometry for 
determination of a ternary mixture containing drotaverine hydrochloride, caffeine 
and Paracetamol29.
14. Ruiz  TP  et  al;  carried  out  the  analysis  of  binary  mixtures  of  flufenamic, 
meclofenamic  and  mefenamic  acids  by  derivative  synchronous  fluorescence 
spectrometry.   The  method  is  based  on  the  intrirsic  fluorescence  of  these 
compounds in chloroform, Serum samples are treated with trichloroacetic acid to 
remove  the  proteins,  an  the  analytes  are  extracted  in  chloroform  Prior  to 
determination30.
15. Nebot C et al;  Studied the Quantification of human pharmaceuticals in water 
samples of high performance liquid chromatography – tandem mass spectrometry 
31.
16. Hung cy et al;  carried out the Analysis of Ketoprofen and mefenamie acid by 
high – performance liquid chromatography with molecularly imprinted polymer 
as  the  stationary  phase,  A  simple  sensitive  HPLC  method  for  simultaneous 
determination  of  the  above  said,  HPLC  with  UV  detection  (220nm)  was 
performed on an analytical column packed with molecularly imprinted polymer 
(MIP) as the stationary phase32.
17. Yogini  jaiswal  et  al;  Studied  the  application  o  HPLC  for  the  simultaneous 
determination of Ethamsylate and mefenamic acids in Bulk Drugs and Tablets 
used with PDA detection.  Ibuprofen was used as the internal standard, which 
made the analyses more accurate33.
18. P.P.Dahivelkar  et  al;  carried  out  the  simultaneous  derivative  and 
multicomponent  spectrophotometric  determination of  drotaverine hydrochloride 
and  mefenamic  acid  in  tablets.   Both  the  drugs  obey  the  Beer’s  law  in  the 
Concentration range employed for these methods34.
19. Bier- MC et al; carried out the determination of olmesartan medoxomil in tablets 
by UV – Vis spectrophotometry.  The Solutions of standard, tablets and synthetic 
tablets were prepared in acetonitrile an NaoH – water, at 258 nm and 250 nm 
respectively.  The method was validated.  The linearity range of method was 1.0 – 
70.0 mg tml -1 and 1.0 – 75.0 mg tmL-1 for acetonitrile and NaoH respectively35.
20. Jiang – JJ et al;   evaluated the relative bioavilability of olmesartan medoxomil 
tablet (test)  versus capsule (reference).   20 healthy male volunteers received a 
single crossover dose of test  and reference olmesartan medoxomil 20mg.  The 
plasma concentrations of olmesartan were determined by HPLC36.
21. CHEN  –  m  et  al;  carried  out  the  High  performance  liquid  chromatography 
determination of the olmesartan medoxomil and hydrochlorothiazide tablets, with 
Potassium  hydrogen  phosphate  (PH  3.6  adjusted  with  phosphoric  acid) 
acetonitrile (50:50) with flow rate of lml 37.
22. Murakami T et al;  studied the identification of degradation product in stressed 
tablets of olmesartan medoxomil by the complementary use of HPLC Hyphenated 
techniques 38.  
23. Liv D et al;  Carried out the Quantitative determination of olmesartan in human 
plasma and urine by liquid chromatography coupled to tandem mass spectrometry 
(HPLC  –  MS  /  MS)  Solid  phase  extraction  (SPE)  was  used  to  isolate  the 
compounds from biological matrix followed by injection of the extracts onto a 
C(18) column with isocratic elution 39.
24. Celebier et al; Carried out the determination of olmesartan medoxomil in tablets 
by UV – Visible spectrophotometry 40.
25. Najma sultana et al;   carried out the simultaneous determination of olmesartan 
medoxomil  and  irbesartan  and  hydrochlorothiazide  in  pharmaceutical 
formulations and human serum using high performance liquid chromatography. 
Good chromatographic separation was achieved using a µ-BondPak, C18 column 
The ultraviolet detector was set at a wave – length of 260 nm 41.
26. Valizedh  H  et  al;  developed  a  simple  and  rapid  high  performance  liquid 
chromatography  method  with  UV  detection  at  280  nm  for  simultaneous 
quantitation of furosemide and hydrochlorothiazide along with phenol red as a 
non absorbable marker for in situ permeability studies in anathetized rats42.
27. Ramakrishna NV et al;   developed a sensitive liquid chromatography tandem 
mass spectrometery method for quantification of hydrochlorothiazide in human 
plasma, tamsulosin was internal standard extracted by liquid – liquid extraction 
with diethyl ether – dichloromethane (70:30, v/v) using a glas – col malti pulse 
Vortexer 43.
28. Henion  JD  et  al;  carried  out  the  qualitative  and  quantitative  analysis  of 
hydrochlorothiazide  in  equine  plasma  and  urine  by  high  performance  liquid 
chromatography.  Thin layer chromatography is used to screen for the presence of 
the drug in unknown samples.  An internal standard, trichloromethiazide is used 
to  derive  quantitative  data  at  concentrations  as  low as  25ng  /  ml  for  plasma 
disappearance curves and urinary excretion rates 44.
29. Zendelovska  D  et  al;  Developed  a  solid  phase  extraction  method  and  its 
application  for  determination  of  hydrochlorothiazide  in  human  plasma  using 
HPLC 45.
30. Abdel Razak O et al; developed a electrochemical study of hydrochlorothiazide 
and its determination in urine and tablets.  The voltametric study of (HCTZ) at 
glassy carbon electrode was carried out, the drug in Britton – Robinson buffer 
(PH 3.3)  is  oxidized  at  +1040mv giving rise  to  a  well  defined peak.   Cyclic 
Voltametric study indicates that the oxidation process is irreversible and diffusion 
controlled 46.
31. Garg G et al;  developed a sepectrophotometric and column high Performance 
liquid chromatographic  methods for  simultaneous estimation of  metoprolol  for 
simultaneous estimation of metoprolol tartrate and hydrochlorothiazide in tablets 
Paracetamol was used as internal standard 47.
32. Lusis ML et al;  carried out the Simultaneous spectrophotometric determination 
of  diuretics  by  using  multivariate  calibration  methods,  under  the  optimum 
conditions thus established,  synthetic mixtures of the analytes can be resolved 
with errors and RSD less than 4.5 and 1.0% respectively 48.
33. Maggio  RM  et  al;  developed  a  multivariate  approach  for  the  simultaneous 
determination  of  losartan  Potassium  and  hydrochlorothiazide  in  a  combined 
pharmaceutical tablet formulation49.
34. Obando  MA  et  al;  carried  out  the  simultaneous  determination  of 
hydrochlorothiazide and lorsartan Potassium in tablets by high Performance low 
Pressure chromatography using a multi syringe burette coupled to a monolithic 
column.   The  system comprised  a  multi  syringe  module,  three  low  Pressure 
solenoid Valves, a monolithic c(18) column and a diode array detector 50.
35. Menon  GN  et  al;  carried  out  the  simultaneous  determination  of 
hydrochlorothiazide and triamterene in capsule formulations by high performance 
liquid chromatography.  Recoveries of the two drugs added to placebos ranged 
from 98.4 to 101.7 1% 51.
36. Vrani CE et al; studied the influence of tablet splitting on content uniformity of 
lisinopril / hydrochlorthiazide tablets.  The aim of this study was to tablets.  The 
aim of this study was to establish possible influence of tablet splitting on content 
uniformity of lisinopril and hydrochlorthiazide was carried out by HPLC Method. 
The  results  of  content  uniformity  studies  for  halves  of  tablets  containing 
combination of lisinopril – hydrochlorthiazide (supposed to contain 50% of stated 
20 / 12.5 mg in the whole tablet) were 49.60 + /- 3.29% and 49.29 +/- 0.60% 
*lisiropril); 50.33 +/- 3.50% and 50.69 +/- 1.95% (hydrochlorthiazide) 52.
37. Uchida Y et al; carried out the multi channel liquid chromatography tandem mass 
spectrometry  cocktail  method  for  comprehensive  substrate  characterization  of 
multidrug resistance – associated Protein 4 transporter 53.
38. Song  M  et  al;  carried  out  the  simultaneous  determination  of  amiloride  and 
hydrochlorothiazide in human plasma by liquid chromatography / tandem mass 
spectrometry with Positive / negative ion switching electrospray ionization 54.
39. Gao  J  et  al;  developed  a  liquid  chromatography  /  negative  ion  electrospray 
tandem mass spectrometry method for the quantification of rosuvastatin in human 
plasma,  application  to  a  pharmacokinetic  study,  using  hydrochlorothiazide  as 
internal standard55.
40. L  I  H  et  al;  developed  liquid  chromatography  /  tandem  mass  spectrometry 
method for the simultaneous quantification of valsartan and hydrochlorthiazide in 
human plasma 56.
41. Nirogi  RV et  al;  developed  a  simple  and rapid  HPLC /  UV method  for  the 
simultaneous quantification of theophylline  and etofylline in human plasma, the 
analytes  and  internal  standard  hydrochlorothiazide  were  separated  using  an 
isocratic mobile phase on a reverse phase C18 column 57.
42. Vonapartic  A  et  al;  studied  the  development  and  validation  of  a  liquid 
chromatographic  /  electrospray  ionization  mass  spectrometric  method  for  the 
determination  of  benazepril,  benazeprilat  and  hydrochlorothiazide  in  human 
plasma58.
43. Quaglia  MG  et  al;  carried  out  the  determination  of  losartan  and 
hydrochlorthiazide  in  tablets  by  CE  and  CEC  (capillary  electrophoresus)  and 
capillary Electrochromatography respectively.  The mobile phase was a mixture 
of 50 mm ammonium acetate pH 7, water acetonitrile (1/1.5 / 7.5) 59.
44. Jonczyk A et al;  studied the determination of hydrochlorothiazide, triamterene 
and  propranolol  hydrochloride  by  the  spectrophotometric  method  and  high 
performance liquid chromatography 60.
45. Shah  SA  et  al;  studied  the  simultaneous  determination  of  losartan  and 
hydrochlorothiazide in combined dosage forms by first  derivative spectroscopy 
and high performance thin layer chromatography The mobile phase of chloroform 
– methanol – acetone – formic acid was used in HPTLC, 2 well separated and 
sharp peaks for LST AND HCTZ were obtained at Rf values of 0.61 +/- 0.02 and 
0.41 +/- 0.02 respectively 61.
46. Franolic  JD  et  al;  Determined  the  isolation  of  a  2:1  hydrochlorothiazide 
formaldehyde  adduct  impurity  in  hydrochlorothiazide  drug  substance  by 
preparative chromatography and characterization by electrospray ionization LC – 
MS 62.
47. Satana E et  al;  carried  out  the  simultaneous  determination  of  valsaratan  and 
hydrochlorothiazide  in  tablets  by  first  derivative  ultraviolet  spectrophotometry 
and LC.  The derivative procedure was based on the linear relationship between 
the drug concentration and the first derivative amplitudes at 270.6 and 335 nm for 
valsartan and hydrochlorothiazide respectively 63.
48. EI Gindy et al;  studied the application of LC and HPTLC densitometry for the 
simultaneous determination of benapril hydrochloride and hydrochlorothiazide 64. 
49. Er.K N et al;  developed the Analysis of binary mixtures of losartan Potassium 
and hydrochlorothiazide by using high performance liquid chromatography, ratio 
derivative  spectrophotometric  and  compensation  technique.   The  first  method 
based on HPLC on a RP column using mobile phase 0.01 N sodium di hydrogen 
phosphate : methanol : acetonitrile (8:2:1 v/v/v) PH 5.5 with detection at 265.0 
nm.  The second method involves the ratio spectra at 238.360 nm and at 230, 
425nm were  selected  to  determine  losartan  Potassium and  HCTZ.   The  third 
method based on compensation technique is presented for the derivative technique 
is  presented  for  the  derivative  spectrophotometric  determination  of  binary 
mixtures with overlapping spectra 65.
50. Zecevic M et al;  studied the use of a response surface methodology on HPLC 
analysis of methyldopa amiloride and hydrochlorothiazide in tablet dosage form 66 
.
51. Banaglu  E  et  al;  Studied  the  Dissolution  tests  of  benazepril  –  Hcl  and 
hydrochlorothiazide  in  Commercial  tablets:  Comparison  of  spectroscopic  and 
high performance liquid chromatography methods67.
52. Belal F et al; developd A stability indicating LC Method for the simultaneous 
determination of ramipril  and hydrochlorothiazide in dosage forms.   Detection 
was  affected  spectrophotometrically   at   210nm.   Clobazam was  used  as  an 
internal standard68.
53. Meduedovici A et al; developed a liquid extraction and HPLC– DAD assay of 
hydrochlorothiazide  from  plasma  for  a  bioequivalence  study  at  the  lowest 
therapeutic  dose.   The  main  parameters  considered  in  optimizing  the  liquid 
extraction and quantitative assay were the yield, precision limit of quantification, 
time  required  for  extraction  and  oncentration  and  quanity  of  solvent.   The 
influence on these parameters of the following factors was examined; nature of 
the extracting solvent, quantity of sovent, co-extraction solvent, and duration of 
stirring.   Instead  of  equilibrium  parameters  of  the  involved  thermodynamic 
system,  a  kinetic  approach  was  preferred  in  terms  of  the  effective  partition 
‘constant’  which  is  not  really  constant  but  a  function  of  time  and  extraction 
condition 69.
54. Zecevic M et  al;  development  the statistical  optimization of a reversed phase 
liquid  chromatographic  method  for  the  analysis  of  amiloride  and 
hydrochlorothiazide in tablets 70.
55. Kartal  M  et  al; carried  out  the  simultaneous  determination  of 
hydrochlorothiazide  and  amiloride  hydrochloride  by  ratio  spectra  derivative 
spectrophotometry and high performance liquid chromatography 71.
56. Panderi  IE  et  al; carried  out  the  simultaneous  determination  of  benazepril 
hydrochloride  and hydrochlorothiazide  in  tablets  by  second –  order  derivative 
spectrophotometry72.
57. Panderi  IE  et  al; carried  out  the  simultaneous  determination  of  benazepril 
hydrochloride and hydrochlorothiazide by micro–bore liquid chromatography 73.
58. Forthing  D  et  al; developed  a  simple  method  for  determination  of 
hydrochlorothiazide in human urine by high performance liquid chromatography 
utilizing narrowbore chromatography 74.
59. Revelle  LK  et  al; studied  the  indentification  of  chlorothiazide  and 
hydrochlorothiazide UV – A photolytic decomposition products 75
60. Richter  K et  al; developed  a  new sensitive  method  for  the  determination  of 
hydrochlorothiazide in human serum by high performance liquid chromatography 
with electrochemical detection76
61. el walily et al;  carried out the simultaneous determination of enalapril maleate 
and hydrochlorothiazide by first derivative ultraviolet spectrophotometry and high 
performance  liquid  chromatography  with  mobile  phase  acetonitrile  –  water 
(20:80, v/v) (PH 3.8) with Programmable detection at 215 and 275 nm 77
62. Thomas  BR  et  al; developed  and  validated  micellar  electrokinetic  capillary 
chromatography  method  for  quality  control  of  the  drug  substance 
hydrochlorothiazide and chlorothiazide78
63. de Vries et al; carried out the simple determination of hydrochlorothiazide in 
human plasma and urine by high performance liquid chromatography79.
64. Kuo  BS  et  al; developed  column  switching  high  performance  liquid 
chromatographic  (HPLC)  determination  of  hydrochlorothiazide  in  rat  dog  and 
human plasma. The method involves direct injection of plasma to the extraction 
column for sample clean up followed by switching onto the analytical column. 
Good  Precision  accuracy  and  linearity  were  obtained  over  a  range  of  25  to 
2000ng/ml in rat, dog and human plasma80.
65. Ba chman wj et al; carried out the  HPLC photolysis electrochemical detection in 
pharmaceutical analysis, application to the determination of spironolactone and 
hydrochlorothiazide in tablets81.
66.  Stewart  JT  et  al; developed  the  liquid  chromatographic  determination  of 
quanethidine salts and hydrochlorothiazide using electrochemical detection and 
ion pair techniques82.
67. Barbhaiya  RH  et  al;  carried  out  the  High  Pressure  liquid  chromatographic 
determination  of  chlorothiazide  and  hydrochlorothiazide  in  plasma  and  urine: 
preliminary results of clinical studies83.
68.  Ouyang J et al;  carried out the flow injection of hydrochlorothiazide applying 
sensitized chemileminescence detection, optimisation in view of narrow bore – 
HPLC 84.
69. Khedr A et al; studied 3 – bromo methyl – prophenazone as a new derivatization 
reagent  for  high  performance  liquid  chromatography  of  captopril  and 
hydrochlorothiazide with UV detection 85.
OBJECTIVE AND PLAN OF WORK 
 Drotaverine Hydrochloride and Mefenamic acid an Antispasmodic and Analgesic 
drug combination in combined dosage form, is being considered for analysis by 
UV  spectrophotomeric  simultaneous  equation  method  as  λ max  of  drug  is 
dissimilar and their absorbance ratio lies outside the range 0.1 to 2. The next aim 
is  to  develop  and   validate  a  reverse  phase  high  performance  liquid 
chromatography in accordance with USP and ICH guidelines for the assay of the 
active ingredients  which would be simple,  rapid,  efficient  and reliable  for  the 
analysis of both the drugs in combined dosage form.
 Olmesartan  Medoxomil  and  Hydrochlorothiazide  an  Antihypertensive  and 
Diuretic  drug  combination  in  combined  dosage  form,  is  being  considered  for 
analysis by UV spectrophotomeric simultaneous equation method as  λ max of 
drug is dissimilar and their absorbance ratio lies outside the range 0.1 to 2. The 
next  aim is  to  develop  and  validate  a  reverse  phase  high  performance  liquid 
chromatography in accordance with USP and ICH guidelines for the assay of the 
active ingredients  which would be simple,  rapid,  efficient  and reliable  for  the 
analysis of both the drugs in combined dosage form.
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 DRUG PROFILE 
DROTAVERINE HYDROCHLORIDE
Molecular Structure
 Chemical Name 
1,2,3,4-Tetrahydro-6,7-diethoxy-1-((3,4-diethoxyphenyl) methylene)-
isoquinoline hydrochloride
 Molecular Formula
C24H31NO4.HCl;C24H32ClNO4
 Molecular Weight
433.97
 Physical State 
Yellow  crystalline Powder 
 Solubility 
Insoluble in water and soluble in 0.1N NaoH, Methonal 
 Therapeutic Category 
Isoquinolone, Antispasmodic agents   
 Mechanism of Action 
Drotaverine  has  antispasmodic  affect  medicated  via  inhibition  of 
phosphodiesterase–IV specific for smooth muscle. It has a rapid and direct action 
on the smooth  muscle. It acts to correct cyclic AMP and Ca imbalance at the 
spastic site thereby relieving smooth muscle spasam  and pain.  
MEFENAMIC ACID
Molecular Structure
 Chemical Name 
Dimethylphenyl)amino]benzoic acid; 
N-(2,3-Xylyl)anthranilic acid
 Molecular Formula
C15H15NO2
 Molecular Weight
241.29
 Physical State 
White  Powder 
 Solubility 
Insoluble in water and soluble in 0.1N NaoH, 0.1N HCL 
 Therapeutic Category 
Analgesic & NSAID
 Mechanism of actions 
Mefenamic acid  inhibits the enzymes cycloxygenase  Cox-1 and Cox-2 and 
reduce the formation of prostaglandin and leukotrienes. It also act as an antagonist 
at prostaglandin  receptor sites. It has Analgesic and Antipyretic properties with 
minor anti inflammatory activity.
UV SPECTROPHOTOMETRIC SIMULTANEOUS EQUATION METHOD OF 
MEFENAMIC ACID AND DROTAVERINE HYDROCHLORIDE IN 
COMBINED TABLET DOSAGE FORM
PRINCIPLE:
If a sample contains two absorbing drugs (X and Y) each of which absorbs at the 
λmax of the other.  It  may be possible to determine the quantity of both drugs by the 
technique of simultaneous equation (or) Vierodt’s method.
Criteria  for  obtaining  maximum precision,  based  upon absorbance  ratios  have 
been suggested that place limits on the relative concentrations of the component of the 
mixture.
A2 / A1 and ay2 / ay1
ax2 / ax1 A2 / A1
Where ax1, ax2 = Absorptivities of X at λ1 and λ2
ay1, ay2 = Absorptivities of X at λ1 and λ2
A1, A2 = Absorbances of the diluted sample at λ1 and  λ2.
The ratio should lie outside the range of 0.1 – 2.0 for the precise determination of 
(Y and X) two drugs respectively.
These  criteria  are  satisfactory  only  when  the  λmax of  the  two  components  is 
reasonably  dissimilar.  The  additional  criteria  includes  that  two  components  do  not 
interact chemically, there by negating the initial assumption that the total absorbance is 
the sum of the individual absorbance’s.
MATERIALS
Market Sample: DROTIN -M
                                   WALTER BUSHNELL
Label claim: 
               Mefenamic acid 250mg
                    Drotaverine hydrochloride 80mg
Equipments Used:
 ATCO Balance
 SHIMADZU UV - & spectrophotometer double beam digital
UV-1700
Solvent Used:
 Methanol AR
                                 
FIXATION OF VARIOUS PARAMETERS (Mefenamic acid)
λmax
The wavelength at which maximum absorption takes is place called λmax
Determination of Absorption Maximum(λmax) for                Mefenamic acid
Procedure:
30mg  of  authentic  Mefenamic  acid  sample  was  accurately  weighed  and 
transferred  to  50ml  volumetric  flask  and    methanol  was  added,  dissolved  and  the 
volume was made upto 50ml with methanol.
5ml of this stock solution was pipetted out in to separate 100ml volumetric flask 
and the volume was made up to 100ml with methanol.
The absorbance of solution was measured against solvent blank in UV-region of 
200-400nm. The λmax was found to be 236nm. This spectrum of maximum absorbance is 
shown in graph.
BEER’S LAW PLOT FOR  MEFENAMIC ACID
PROCEDURE
100mg  of  authentic  Mefenamic  acid  sample  was  accurately  weighed  and 
transferred  to  100ml  volumetric  flask  and  methanol  was  added,  dissolved  and  the 
volume was made up to 100ml with methanol.
 From this aliquots of 0.5ml, 1ml, 1.5ml, 2ml, 2.5ml, 3ml, 3.5ml, 4ml, 4.5ml, 5 ml 
was pipetted out in to separate 100ml volumetric flask. Then the volume was made upto 
100ml with methanol. The absorbance of each solution was found out at 236nm against 
a reagent blank. The readings are presented in Table-1 and graph.
   
Table – 1
DATA FOR BEER’S LAW PLOT FOR  MEFENAMIC ACID (Linearity)
S.No. Concentration μg/ml Absorption
1 5 0.1192
2 10         0.2382
3 15 0.3573
4 20 0.4766
5 25 0.5956
6 30 0.7147
7 35 0.8338
8 40 0.9529
9 45 1.0720
10 50 1.1911
Linearity Co-efficient (γ ) = 0.999
SLope (m)  = 0.023820
 Intercept(c)                      = - 0.000056
       
DEVIATIONS FROM BEER’S LAW
For the drug  Mefenamic acid maximum deviation was found in the 
Concentration range above 50μg/ml.  The readings are presented in 
Table -2 and graph. 
Table -2
DATA FOR DEVIATIONS FORM BEER’S LAW PLOT FOR                
MEFENAMIC ACID
S.No. Concentration μg/ml Absorbance
1. 5 0.1192
2. 10              0.2382
3. 15 0.3573
4. 20 0.4766
5. 25 0.5956
6. 30 0.7147
7. 35 0.8338
8. 40 0.9529
9. 45 1.0720
10. 50 1.1911
11 55 1.3104
12 60 1.2603
13 65 1.2601
14 70 1.2599
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Determination  of  Absorption  Maximum  (λmax)  Drotaverine 
hydrochloride
Procedure:
100mg  of  authentic Drotaverimne  hydrochloride  sample  was 
accurately weighed and transferred to 50ml volumetric flask and methanol 
was added, dissolved and the volume was made upto 50ml with methanol
5ml of this stock was pipetted out in to separate 100ml volumetric flask and 
the volume was made up to 100ml with methanol
The absorbance of solution was measured against solvent bank in UV-
region of 200-400 nm.  The λ max was found to be 245nm.  This spectrum of 
maximum absorbance is shown in graph.
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BEER’S LAW PLOT FOR DROTAVERINE HYDROCHLORIDE
PROCEDURE
100mg of authentic Drotaverine Hydrochloride sample was accurately 
weighed and transferred to 100ml volumetric flask and methanol was added, 
dissolved and the volume was made up to 100ml with methanol. 
From this aliquots of 0.5ml, 1ml, 1.5ml, 2ml, 2.5ml, 3.ml, 3.5ml, 4ml, 
4.5ml,5ml,  was pipetted out in to separate 100ml volumetric flask.  Then the 
volume  was  made  upto  100ml  with  methanol.   The  absorbance  of  each 
solution was found out at 245nm against a reagent blank.  The readings are 
presented in Table-3 and graph
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TABLE-3
DATA FOR BEER’S LAW PLOT FOR DROTAVERINE 
HYDROCHLORIDE
S.No. Concentration μg/ml Absorbance
1. 5 0.07645
2. 10 0.1529
3. 15 0.2293
4. 20 0.3058
5. 25 0.3822
6. 30 0.4587
7. 35 0.5351
8 40 0.6116
9 45 0.6880
10 50 0.7645
Linearity coefficient γ = 0.9999
Slope(m) = 0.01527
Intercept(c) = -0.00053
DEVIATIONS FROM BEER’S LAW
For the drug, Drotaverine Hydrochloride maximum deviation 
was found in the concentration range above 55μg/ml .The readings are 
presented in Table –4 and graph.
Table – 4
Data for Deviations from Beer’s law plot for Drotaverine 
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Hydrochloride
S.No. Concentration μg/ml Absorption
1 5 0.07645
2 10 0.1529
3 15 0.2293
4 20 0.3058
5 25 0.3822
6 30 0.4587
7 35 0.5351
8 40 0.6116
9 45 0.6880
10 50 0.7645
11 55 0.6920
12 60 0.6915
13 65 0.6910
14 70 0.6909
   
Preparation of Mefenamic acid standard solution
100mg of authentic Mefenamic acid sample is accurately weighed 
and transferred to 100ml volumetric flask and methanol was added and 
shaken  until  it  dissolves  and  the  volume was  made  upto  100ml  with 
methanol.
From this 1ml was pipetted out in to separate 100ml volumetric 
flask and the volume was made up to 100ml with methanol.
Preparation of Drotaverine hydrochloride standard solution
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100mg  of  authentic  Drotaverine  hydrochloride  sample  is 
accurately  weighed  and  transferred  to  100ml  volumetric  flask  and 
methanol was added and shaken until it  dissolves and the volume was 
made upto 100ml with methanol.    
 From this 1ml was pipetted out in to separate 100ml volumetric 
flask and the volume was made up to 100ml with methanol.
The absorbance and absorptivity values are shown un Table-5a & 5b
Preparation of sample solution
Twenty  tablets  are  weighed and average  weight  was  calculated. 
The tablets are ground to a fine powder. A powder equivalent to 250mg 
of Mefenamic  acid   and  80mg  of  Drotaverine  hydrochloride  was 
accurately  weighed  and  transferred  to  50ml  volumetric  flask  and 
methanol was added and shaken until it  dissolves and the volume was 
made  upto  50ml  with  methanol.  This  solution  was  filtered  through 
whatmann filter paper. 
From this 1ml was pipetted out in to separate 100ml volumetric 
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flask and the volume was made up to 100ml with methanol.
The absorbance of each solution was found out at 236nm (λmax of 
Mefenamic  acid  )  and  245nm  (λmax of Drotaverine hydrochlororide) 
against a reagent blank.
The analysis values are given in Table-6.
Calculation:
λ1 = 236nm (λmax of Mefenamic acid)
λ2 = 245nm ( λmax of Drotaverine hydrochloride )
X – Mefenamic acid
Y – Drotaverine hydrocholoride
ax1 and ax2 – Absorptivities of Mefenamic acid  at  λ1 and λ2
ay1 and ay2 – Absorptivities of  Drotaverine hydrocholoride at λ1 and λ2 
Cx  and  Cy  –  Concentration  of  Mefenamic  acid   and  Drotaverine 
hydrochloride  (Sample) in grams per 100ml
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A1 and A2 – Absorbance of sample at λ1 and λ2    
Absorptivity (a) = A/bc = Absorbanceb x concentration of substance
Determination of Cx and Cy
Cx = A2ay1-A1ay2ax2 ay1- ax1 ay2
Cy = A1ax2-A2ax1ax2 ay1- ax1 ay2
Table-5a
Absorbance values for standard and sample
Wavelength Olmesartan medoxomil Hydrochlorothiazide Sample
236
λ1
Mefenamic acid
0.2383 (X1) 0.1021 (Y1) 0.8452 (A1)
245
λ2
Drotaverine 
hydrochloride
0.1447(X2) 0.1529(Y2) 0.6024 (A2)
Table-5b
Absorptivity values for Mefenamic acid and Drotaverine 
Hydrochloride
Parameter
Absorptivity at  236nm Absorptivity at 245nm
Mefenamic 
acid
Drotaverine 
Hydrochloride
Mefenamic 
acid
Drotaverine 
Hydrochloride
*Mean ax1=238.2 ay1=102.1 ax2= 144.1 ay2=152.9
SD 0.3791 0.2455 0.4207 0.1645
*   Absorptivity  values  are  the  mean  of  six  determinations.  S.D.  is 
standard deviation.  ax1 and ax2 are absorptivities of Mefenamic acid at 
236nm  and  245nm   respectively;  ay1  and  ay2  are  absorptivities  of 
Drotaverine hydrochloride at 236nm and 245nm respectively.
CRITERIA FOR OBTAINING MAXIMUM PRECISION
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                               (A2 / A1)/ (ax2 / ax1)  and (ay2 / ay1)/ (A2 / A1) 
was found to be 0.043098 & 2.06735  respectively. This ratio should lie 
outside the range 0.1-2.0 for the precise determination.
Table-48
Analysis data of tablet formulations
Parameters
UV-spectrophotometry
Mefenamic 
acid
Drotaverine
Hydrochloride
Label Claim 250mg 80mg
Amount found 2.49mg 79.96mg
*% Drug content 99.8 99.95
S.D. 0.2739 1.1516
% R.S.D 0.2724 1.1698
RECOVERY STUDIES
To check the accuracy of the developed method and to study the 
interference  of  formulation  additives,  analytical  recovery  experiments 
were carried out by standard addition method at 80, 100 and 120% level. 
From  the  total  amount  of  drug  found  the  percentage  recovery  was 
calculated. The results are reported in Table-7
Table 7
Recovery studies
Mefenamic acid
Range Amount found *Recovery % R.S.D
80% 249.55mg 99.80% 0.0995
100% 249.58mg 99.80% 0.1892
120% 249.59mg 99.83% 0.09
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Drotaverine Hydrochloride 
Range Amount found *Recovery % R.S.D
80% 79.98mg 99.90% 0.3213
100% 79.96mg 99.95% 0.1219
120% 79.92mg 99.90% 0.1928
*Recovery is the mean of three estimations
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DEVELOPMENT AND VALIDATION OF REVERSE PHASE 
HIGH PERFORMANCE LIQUID CHROMATOGRAPHY OF 
DROTAVERINE HYDROCHLORIDE AD MEFENAMIC 
ACID IN COMBINED TABLET DOSAGE FORM
INSTRUMENTS 
 Shimadzu
 UV Visible SPD – 20A
 LC 20AT Isocratic
 Rheodyne
 C18.
Regents and Chemicals
 Acetonitrile
 HPLC grade water
 Buffer
 Methanol
REFERENCE STANDARDS :
Drotaverine hydrochloride and mefenamic acid
These two reference standards were obtained as gift samples from 
Dr. Ceeal Lab, Chennai.  The authenticity and purity of the sample was 
certified by the same. 
Sample Tablet brand used : DROTIN – M
    Dr. Ceeal Lab, Chennai.
Label claim : Drotaverine hydrochloride 80 mg
Mefenamic acid 250 mg
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METHOD DEVELOPMENT AND OPTIMIZATION :
SELECTION OF WAVELENGTH :
The   known  concentration  of  Drotaverine  hydrochloride  and 
Mefenamic acid were taken and dissolved in methanol.  The wavelength 
were tried at 250nm, 260nm, 270nm, and the Peaks of the drugs were 
showing fronting and tailing.  240nm were selected for the analysis.
OPTIMIZATION OF CHROMATOGRAPHIC PARAMETERS 
(a) SELECTION OF MODE OF OPERATION:
As both the drugs were are polar in nature, a RP-HPLC method 
was proposed.
(b)SELECTION  AND  STANDARDISATION  OF  MOBILE 
PHASE :
DROTIN –M   is combination of Drotaverine hydrochloride 80 mg 
and mefenamic acid 250 mg.  The method development of Drotaverine 
hydrochloride and mefenamic acid required adequate resolution of two 
drug peaks in the chromatogram.
DIFFERENT COMBINATIONS OF BUFFER AND SOLVENTS:
Buffer Potassium di hydrogen phosphate and acetonitrile (70:30)
Buffer Potassium di hydrogen phosphate  and acetonitrile (50:50)
Buffer  Potassium  di  hydrogen  phosphate  acetonitrile  (50:50) 
Buffer potassium di hydrogen :  Methanol:acetonitrile (50:15:35)
Peaks of Drotaverine Hydrochloride and mefenamic acid were well 
resolved  with  solvent  system.  Buffer  Potassium  di  hydrogen 
phosphate :  methanol:  acetonitrile  (50:15:35) and it  is  shown in 
figure-1.
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SELECTION OF FLOW RATE :
The Flow rate for Drotaverine HCL and Mefenamic acid were tried 
with 0.4ml, 0.5ml, and 0.7ml and the peaks of the drugs were showing 
fronting and tailing with 0.4ml and 0.7ml respectively and finally 1.5ml 
per minute was selected for the analysis.
PREPARATION OF BUFFER SOLUTION :
Buffer  solution  was  prepared  by  using  1.3609gm of  Potassium 
di  hydrogen  of  HPLC  grade  water,  filtered  through  0.45u  nylon 
membrane and degassed.
PREPARATION OF MOBILE PHASE :
Mix the Buffer, methanol: and acetonitrile in the ratio of 50:15:35 
and degass it.  Filtered through 0.45u membrane.
DILUENT
Mobile phase is used as diluent.
DETERMINATION OF RETENTION TIME :
(A) PREPARATION OF STANDARD SOLUTION OF 
DROTAVERINE HYDROCHLORIDE
Accurately 0.08g Drotaverine hydrochloride was taken in a 100ml 
volumetric  flask  and  the  volume  was  adjusted  to  100ml  with 
mobile phase. 5ml was taken in a separate 50ml volumetric flask 
and the volume was adjusted to 50 ml with mobile phase to get 
concentration of 80  µgl/ml Drotaverine hydrochloride of 20µl  of 
this solution was injected and chromatogram was obtained and it is 
in shown Figure-3.
(B)  PREPARATION STANDARD SOLUTION OF MEFENAMIC 
57
ACID 
Accurately 0.250g was taken in a 100ml volumetric flask and the 
volume was adjusted to 100ml with mobile phase.  5 ml was taken in a 
separate volumetric flask of 50ml and the volume was adjusted to 50ml 
with  mobile  phase  to  get  a  concentration  of  250  µg/ml.  20µl  of  this 
solution was injected and the chromatogram was recorded and shown in 
Figure-2.
(C) PREPARATION OF MIXED STANDARD SOLUTION :
0.08g of Drotaverine hydrochloride and 0.250g of Mefenamic acid 
was transferred into a 100ml dried volumetric  flask.   The compounds 
were first dissolved in 20ml of mobile phase and it was sonicated. Then 
the volume was adjusted to 100ml with mobile phase.  From the stock 
solution 5ml was transferred to a 50ml volumetric flask and the volume 
was  adjusted  to  50ml  with  mobile  phase  to  get  a  concentration  of 
80µg/ml  of  Drotaverine  hydrochloride  and   250µg/ml  of  Mefenamic 
20µl  if  the  resulting  solution  was  injected  and  chromatogram  was 
recorded shown in Figure-4.
FIXED CHROMATOGRAPHIC CONDITIONS :
INSTRUMENT : Shimadzu Prominence model
LC 20 AT Isocratic
COLUMN : C18
WAVELENGTH : 240nm
TEMPERATURE : Ambient temperature
FLOW RATE : 1.5ml / mit
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INJECTION VOLUME : 20µl
MOBILE PHASE : Buffer Potassium di hydrogen phosphate
Methanol and acetonitrile 50:15:35
RETENTION TIME : 3.0   for  Mefenamic  Acid   6.4  for 
drotaverine 
QUANTITATIVE DETERMINATION OF THE DRUGS OF THE 
DRUGS BY USING THE DEVELOPED METHOD
Sample : Drotaverine Hydrochloride and 
Mefenamic acid 
Label Claim : Drotaverine hydrochloride 80mg
Mefanamic acid 250mg
METHOD :
Twenty  tablets  were  weighed  and  powdered.   Average  weight 
593.2g  of  sample  tablet  DROTIN  –  M  (equivalent  to  80mg  of 
Drotaverine Hydrochloride and 250mg Mefenamic acid was taken into 
100ml dried volumetric flask.  The powder was first dissolved in 20ml 
mobile phase and sonicated and finally the volume was adjusted to 100ml 
with  mobile  phase.   From this  solution  5ml  was  transferred  to  50ml 
volumetric flask and volume was adjusted to 50ml with mobile phase to 
get  a  concentration of 80µg/ml  of Drotaverine Hydrochloride and 250 
µg /ml  of  Mefenamic  acid.  20µl  of  the solution was  injected and the 
chromatogram obtained is shown in Figure 5.
The amount of Drotaverine Hydrochloride and  Mefenamic acid 
present in the tablet formulation was calculated by comparing the peak 
area of the standard and reports are given in Table-8.
Amount of drug present in the tablet:
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 Sample area          Standard dilution                 Potency
 ____________ x     _______________     x  _________ x Average weight
 Standard Area        Sample dilution                    100
                                      Amount present             
Percentage purity =      ______________ x 100
                                      Label claim
Table – 8
Quantitative Estimation
S.No. Brand 
Name
Content Label 
Claim 
(mg)
Peak 
area
Amount 
present 
(mg)
Percent 
Purity 
% w/v
1. Drotin-M
Drotaverine
Hydro
chloride 
80 mg 868.77 79.56 99.45%
Mefenamic
Acid 
250 mg 2615.75 250.12 100.05%
Acceptance criteria : 98-102% w/v
Assay for Drotaverine HCL
Amount Present =
            868.77        0.08              99.83                
          _______ x ______  x  _________ x  593.2  = 79.56 mg
            869.25      0.5946              100                      
Percentage Purity =  79.56 / 80 x 100 = 100.20 %
Assay for mefenamic acid
Amount Present =
            0.250           99.68                         
          _______ X ______  X     593.2 = 250.12mg
            0.5946         100              79.56mg
Percentage Purity
            250.12  / 250 x  100  = 100.05 %   
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VALIDATION
Validation  of  an  analytical  method  is  a  process  to  establish  by 
laboratory studies that the performance characteristics of the method meet 
the  requirements  for  the  intended analytical  application.   Performance 
characteristics are expressed in terms of analytical parameters.
Design of experiment:
 Specificity
 Linearity and range
 Limit of quantification
 Limit of detection
 Accuracy
 Precision
o System precision
o Method precision
 Robustness
 Ruggedness
 System suitability studies
o Resolution
o Number of theoretical plates
o The tailing factor.
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SPECIFICITY 
The specificity of an analytical methods is ability to measure accurately 
and specifically the analytes in the presence of compounds that may be 
expected to be present in the sample matrix.
Determination 
The specificity of the analytical methods was determined by injecting the 
placebo solution under the same experimental conditions as the assay.
Preparation of placebo 
Placebo  is  prepared  by  mixing  all  the  expcipients  without  active 
ingredients 
Procedure 
 225 mg placebo was accurately weighted and transferred into  25 
ml  volumetric flask and the volume as made to 25 ml  with the 
mobile  phase.  The  solution  was  filtered  through Millipore  filter 
paper  and  degassed.  20  µl  of  this  solution  was  injected  and 
chromatogram was recorded and shown in figure- 6.
 80  mg  drotaverine,  hydrochloride  and  250  mg  mefenamic  acid 
were weighed and  transferred into a 100 ml volumetric flask and 
volume was adjusted to 100 ml with mobile phase. Further 5 ml of 
the solution was taken and the volume was made upto 50 ml to get 
a  concentration of 80  µg/ml Drotaverine hydrochloride  & 250 
µg/ml Mefenamic acid to this solution 90 mg of placebo was added 
and it was sonicated, filtered through a Millipore filter paper. 20 µl 
of  this  solution  was  injected,  chromatogram  was  recorded  and 
shown in  Figure-7  and the report are shown in Table 9 & 10.
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TABLE – 9
SPECIFICITY FOR DROTAVERINE HYDROCHLORIDE 
S.No Sample Area Obtained
1 Standard 869.25
2 Standard + Placebo 877.44
3 Placebo 0
TABLE – 10
SPECIFICITY FOR  MEFENAMIC ACID
S.No Sample Area Obtained
1 Standard 2599.03
2 Standard + Placebo 2596.22
3 Placebo 0
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LINEARITY  AND RANGE
Linearity of an analytical method is its ability to elicit test result that are 
directly proportional to the concentration of analyte in samples within a 
given range.
Determination
The linearity of the analytical method was determined by mathematical 
treatment  of  test  result  obtained  by  analysis  of  sample  with  analyte 
concentration across the claimed range. Area was plotted graphically as a 
function of analyte concentration. Percentage curve fitting was calculated.
Method 
Preparation of mixed standard stock solution 
Accurately  weighted  80  mg  drotaverine  hydrochloride   250  mg 
mefenamic acid were transferred in to the 100 ml of standard flask and it 
was dissolved with mobile phase and the volume was made upto 100ml 
with mobile phase. From the resulting solution 4,4.5, 5, 5.5 6 ml were 
transferred into 5 different 50 ml volumetric flask. The volume was made 
with mobile phase to get a final concentration of 64, 72, 80, 88, 96 µg/ml 
drotaverine  hydrochloride 200, 225 250, 275 300  µg/ml of Mefenamic 
acid. 20µl  up of the resulting solution was injected and chromatogram 
was recorded. 
The chromatograms of Drotaoverine hydrochloride and Mefenamic acid 
are shown in figure 8-12.    
Acceptance Criteria 
Correlation coefficient should not be less than 0.99
The  linearity  datas  and  analytical  performance  parameters  of 
Drotaoverine  hydrochloride  and  Mefenamic  acid  are  shown  in 
Table 11-13 and calibration curve are shown in graph. 
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TABLE – 11
LINEARITY DATA 
DROTAVERINE HYDROCHLORIDE 
S.NO CONCENTRATION (µg/ml) PEAK AREA 
1 64 698.37
2 72 789.02
3 80 872.05
4 88 969.24
5 96 1058.00
Table – 12
MEFENAMIC ACID 
S.NO CONCENTRATION (µg/ml) PEAK AREA 
1 200 2039.59
2 225 2272.73
3 250 2513.72
4 275 2767.59
5 300 3016.84
TABLE – 13
ANALYTICAL PERFORMANCE PARAMETERS
S.NO DRUG 
NAME 
LINEAR 
DYNAMIC 
RANGE 
(U/ML)
CORRELATION 
COEFFICIENT
SLOPE INTERCEPT 
1 Drotaverine 
Hydrochloride
64-96 0.9997 11243.
5
-22.144
2 Mefenamic 
Acid
200-300 0.9998 9797.4
4
72.734
ACCURACY 
The accuracy of  an  analytical  method  is  the closeness  of  the  results 
obtained  by  that  method  to  the  true  value.  Accuracy  may  often  be 
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expressed as percent recovery by the assay of known added amount of 
analyte.
Determination 
The accuracy of the analytical method was determined by applying the 
method to the analysed samples to which known amounts of analyte had 
been  added.  The  accuracy  was  calculated  from the  test  results  as  the 
percentage of analyste recovered by the assay.
Acceptance criteria :
Percentage recovery should be within 98-102 % 
PROCEDURE 
Mixed standard stock solution 2 ml and sample  stock solution 2 ml were 
mixed together in 50 ml volumetric flask and the volume was made upto 
50 ml with mobile phase to get 80 % range. Similarly 100 % and 120 % 
range 
was  prepared   20  µl   of  this  solution  was  injected  three  times  and 
chromatograms were shown in Fig. 13 to 21 and values in table 14 and 
15.
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TABLE -14
RECOVERY STUDY OF DROTAVERINE HYDROCHLORIDE
S.No Range Area 
Obtained
Amount 
Recovered 
(mg)
% Recovery
1
80 %
699.74 80.17 100.21
700.13 80.21 100.27
699.98 80.20 100.25
2
100 %
877.44 80.42 100.53
878.20 80.50 100.62
878.09 80.48 100.60
3
120 %
1057.09 80.74 100.90
1057.12 80.75 100.90
1056.21 80.67 100.80
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TABLE – 15
RECOVERY STUDY MEFENAMIC ACID
S.No Range Area 
Obtained 
Amount 
Recovered 
(mg) 
% Recovery 
1
80 %
2095.22 250.45 100.18
2087.95 249.58 99.83
2093.45 250.24 100.09
2
100 %
2596.22 248.26 99.30
2606.04 249.20 99.68
2597.13 248.35 99.30
3
120 %
3129.21 249.36 99.74
3120.22 248.64 99.45
3117.10 248.40 99.36
68
PRECISION 
Precision  of  an  analytical  method  is  the  degree  of  agreement  among 
individual  test  results  when  the  procedure  is  applied  repeatedly  to 
multiple  sampling  of  a  homogenous  sample.  Precision  of  analystical 
method  is  usually  expressed  as  the  standard  deviation  and  relative 
standard deviation.
Determination : 
The  precision  of  the  analytical  method  was  determined  by  assaying 
sufficient  number  of  sample  and  relative  standard  deviation  was 
calculated.
The precision of the instrument was determined by assaying the samples 
consecutively,  number  of  time  and  relative  standard  deviation  was 
calculated.
Acceptance Criteria 
The relative standard  deviation should be with in 2 %
SYSTEM PRECISION 
Procedure 
Accurately  weighed  80  mg  drotaverine  hydrochloride  and  250  mg 
mefenamic acid were  transferred into 100 ml standard flask and it was 
dissolved  with  mobile  phase.  From the  resulting  solution  50  ml  was 
transferred into 50 ml volumetric flask. The volume was made up with 
mobile phase to 50 ml.
The system precision was evaluated by measuring 6 successive injection 
of 20µl of standard solution. The peak response were measured from the 
chromatogram shown in  figure 22-27 and system precision data  area 
shown in table 16 & 17.
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Method Precision 
Procedure 
Twenty tables were weighted and powdered.  Average weight 593.2 of 
sample  tablet  DROTIN-M  (equivalent  to  80  mg  Drotaverine 
hydrochloride and 250 mg of mefenamic acid)  was taken into 100 ml 
dried volumetric flask. The power was first dissolved in 20ml of mobile 
phase and sonicated and finally the volume was adjusted to 100 ml with 
mobile  phase.  From this  solution 5ml transferred to  50 ml  volumetric 
flask  and  volume  was  adjusted  to  50  ml  with  mobile  phase  to  get  a 
concentration of 80µg/ml of drotaverine  hydrochloride and  250 µg/ml of 
mefenamic  acid  0.20µl  of   the  solution  was  injected  and  the 
chromatogram obtained is shown in Figure 28-33 and method precision 
data are shown in table 18-20.       
TABLE – 16
SYSTEM PRECISION DATA 
S.No Area Drotaverine  Hydrochloride Area of Mefenamic acid
1 877.44 2623.8
2 877.03 2615.65
3 883.41 2599.03
4 876.06 2598.06
5 877.59 2598.10
6 878.29 2614.96
Mean 878.30 2608.27
S.D. 2.6071 11.2722
% 
RSD
0.2968 0.4321
TABLE -17
Relative 
standard 
deviation 
Drotaverine 
Hydrochloride 
Mefenamic acid Acceptance 
Criteria 
0.2968 0.4321 2 %
TABLE – 18 
METHOD PRECISION OF DROTAVERINE HYDROCHLORIDE
S.No Area Obtained Amount Recovered Purity % w/v
1 877.00 78.63 99.54
2 876.98 79.61 99.59
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3 879.99 79.36 99.20
4 877.11 79.77 99.71
5 877.53 79.67 99.58
878.24 79.67 99.58
MEAN 99.53
STANDARD DEVIATION 1.1705
RELATIVE STAND DEVIATION 0.133
Table – 19 Method Precision of Mefenamic acid
S.No Area Obtained Amount Recovered Purity % w/v
1 2619.07 248.08 99.20
2 2618.65 248.82 99.53
3 2615.77 250.13 100.05
4 2619.53 250.59 100.23
5 2617.84 250.41 100.16
6 2618.06 248.80 99.52
MEAN 99.78
STANDARD DEVIATION 1.3243
RELATIVE STAND DEVIATION 0.05
Table – 20 Method Precision report for Drotaverine Hydrochloride 
and Mefenamic Acid
Relative 
standard 
deviation 
Drotaverine 
Hydrochloride 
Mefenamic acid Acceptance 
Criteria 
0.133 0.05 2 %
LIMIT OF DETECTION (LOD )
It is the lowest amount of analyte in a sample that can be detected  but not 
necessary  quantities  as  an  exact  value  under  the stated,  experimental 
conditions. The detection limit is usually expressed as the concentration 
of analyte.
It is given by
LOD = 3.3 xσ
  --------
   m 
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σ = standard deviation of the response 
m = slope of the calibration curve 
      TABLE – 21
LIMIT OF DETECTION 
DRUG STANDARD 
DEVIATION 
SLOPE L.O.D µg/ ml
Drotaverine 
Hydrochloride 
2.6071 11243.5 0.00076519
Mefenamic acid 11.2722 9797.44 0.003796
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LIMIT OF  QUANTITATION
The Quantitation limit of an analytical procedure is the lowest amount of 
analytic which can be quantitatively determined with suitable precision 
and Accuracy.
It is given by
L.O.Q = 10x σ
   ------
    m
σ= Standard deviation of the response 
m=slope of the calibration  curve 
TABLE – 22
LIMIT OF QUANTITATION 
DRUG STANDARD 
DEVIATION 
SLOPE L.O.Q µg/ ml
Drotaverine 
Hydrochloride 
2.6071 11243.5 0.002318
Mefenamic acid 11.2722 9797.44 0.011505
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RUGGEDNESS
The Ruggedness of an analytical method is degree of reproducibility of 
test result obtained by the analysis of the same sample under a variety of 
normal test condition, such as different laboratories, different analyst 
different assay temperature, different days etc.
Ruggedness is normally  expressed as the lack of influence on test  result 
of operational and environmental variables of the analytical method.
 
Determination :
The ruggedness of an analytical method was determined by analysis of 
aliquots from homogenous lots by different analysis using operations and 
environmental  conditions  that  may different  but  were still  with  in  the 
specified parameters of the assay. The degree of reproducibility of test 
result  was  then  determined  as  a  function  of  the  assay  variables.  This 
reproducibility was then determined as a function of the assay variables. 
This  reproducibility  was  assayed  under  normal  conditions  to  obtain  a 
measure of the ruggedness of analytical method.
The  assay  Drotaverine  hydrochloride  and  mefenamic  acid  were 
performed in different conditions  like different analyst on different days.
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METHOD 
The standard  and sample solutions were prepared by different analysts 
on different days and the resulting solution were injected and 
chromatograms are recorded and shown in  Figure 34-37 and ruggedness 
of the method and report of drotaverine hydrochloride and  mefenamic 
acid as shown in  Table 23.
Table -23
RUGGEDNESS
Analyst Date Amount Found % purity
Drotaverine 
hydrochloride 
Mefenamic 
acid  
Drotaverine 
hydrochloride 
Mefenamic 
acid  
I 4Nov 
2008 79.58 mg 248.53 mg 99.48 99.41
II 5Nov 
2008 79.66 mg 250.14mg 99.58 100.05
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ROBUSTNESS
Robustness of an  analytical method is measure of its capacity to remain 
unaffected by small but deliberate variations in method parameters and 
provides  an  indications of its reliability during  normal usage.
Determination 
The robustness of an analytical method was determined by analysis of 
aliquots from homogenous lots by different physical parameters that may 
differ  but  were  still  within  the  specified  parameter  of  the  assay  for 
example change in physical parameters like flow rate and lambda max.
Method 
Standard  solution preparation 
80  mg  Drotaverine   hydrochloride  and  250  mg  mefenamic  acid  were 
transferred into a 100 ml volumetric flask, volume was adjusted to 100 ml 
with mobile phase. Further 5 ml of the solution was taken and the volume 
was made upto 50 ml to get a concentration of 80 µg/ml of drotaverine 
hydrochloride  and 250 µg/ml of mefenamic acid.
Sample preparation 
Twenty tablets were weighted and  powered. Average weight 593.2g of 
sample  tablet DROTIN – M ( equivalent to 80 mg Drotaverine and 250 
mg mefenamic acid was taken into 100 ml dried volumetric flask. The 
powder was first dissolved in 20 ml of mobile phase. From this solution 5 
ml was transferred in to 50 ml volumetric flask and volume was adjusted 
to  100 ml  with  mobile  phase.  20µl  of  this  solution  was  injected  and 
individual chromatograms were recorded and they are in figure 38-45 and 
datas are shown in Table 24-31.   
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TABLE 24
Chromatographic conditions  : - change in flow rate 1.3 ml/ min)
Change in flow rate 1.3 ml / min
Column CN
Wave length 240 nm
Temperature Ambient  250c
Injection volume 20 µl
TABLE 25
Change in flow rate (1.3 ml/ min
S.No Drug standard area sample area % Purity 
w/v
1 Drotaverine 
hydrochloride 
acid  
1347.69 1345.39 99.41
2 Mefenamic 
acid 3896.62 3920.51 100.02
 
TABLE -26
Chromatographic condition :- change in flow rate (1.7 ml/ min) 
Change in flow rate 1.7 ml / min 
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Column CN
Wave length 240 nm
Temperature ambient 250c
Injection volume 20 µl
TABLE 27
Change in flow rate (1.7 ml/ min )
S.No Drug standard area sample area % Purity 
w/v
1 Drotaveraine 
hydrochloride 
acid  
809.02 806.51 99.28
2 Mefenamic 
acid
2305.51 2328.59 100.41
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TABLE -28
Chromatographic condition :- change in Lambda Max 242 nm 
Column CN
Wave length 240nm
Temperature Ambient 250.c
Injection Volume 20 µl
Flow rate 1 ml/ min
TABLE 29
Change in Lambda max 242 nm
S.No Drug standard 
Area 
sample area % Purity 
w/v
1 Drotaverine 
hydrochloride 
712.532 711.27 99.41
2 Mefenamic 
acid
2074.91 2097.42 100.44
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TABLE -30
CHROMATOGRAPHIC CONDITIONS : - CHANGE IN LAMBDA MAX 238 NM
Column CN
Wave length 240 nm
Temperature Ambient 250.c
Injection Volume 20 µl
Flow rate 1 ml/ min
TABLE 31
Change in Lambda  Max   238 nm
S.No Drug Standard 
area 
sample area % Purity 
w/v
1 Drotoverine 
hydrochloride 
867.93 866.32 99.3
2 Mefenamic 
acid
2584.84 2560.68 98.48
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SYSTEM SUITABILITY PARAMETERS 
System  suitability  testing  is  an  integral  part  of  many  analytical 
procedures. The test based on the concept that the equipment, electronics, 
analytical  operation  and  sample  to  be  analysed  constitute  an  integral 
system that can be evaluated as such. System suitability test parameters to 
be established for a particulars procedure depend on the type of procedure 
being validated.
Method 
A  solution  of  80µg/ml  of  Drotaverine  Hydrochloride  and  250µg/ml 
Mefenamic acid were prepared by diluting with mobile phase and same 
was injected and a chromatogram was recorded and they are shown in 
figure 46 and system suitability report are shown in the following.
TABLE – 32
SYSTEM SUITABILITY PARAMETERS
S.No Parameters Drotaverine 
Hydrochloride 
Mefenamic acid 
1 Theoretical plates 12,082,1306 8,361.6466
2 Tailing Factor 1.00 1.00
3 Resolution 6.2
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DRUG PROFILE
OLMESARTAN MEDOXOMIL
 Molecular Structure
 Chemical Name 
4-(1-Hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1H-
tetazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-
imidazole-5-carboxylic  acid  (5-Methyl-2-oxo-1,3-
dioxol-4-yl)methyl ester
 Molecular Formula
C29H30N6O6
 Molecular Weight
558.59
 Physical State 
White to off white powder
 Solubility
Soluble in 0.1N HCL,  0.1N NaoH,  Methanol, 
Insoluble water 
 Therapeutic Category 
Antihypertensive Agent 
 Mechanism Of Action  
Olmesartan is an nonpeptic AT1 angiotension II receptor antagonist 
exerts  antihypertensive  activity  by  preventing  angiotension  II  to 
from binding to AT1 receptors thus inhibiting the vasoconstriction 
and aldosterone – secreting effect of angiotension II. 
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HYDROCHLOROTHIAZIDE 
 Molecular Structure
 Chemical Name 
3,4-Dihydro-6-chloro-7-sulfamoyl-1,2,4-
benzothiadiazine-1,1-dioxide; 6-Chloro-3,4-dihydro-7-
sulfamoyl-2H-1,2,4-benzothiadiazine-1,1-dioxide; 3,4-
Dihydrochlorothiazide
 Molecular Formula
C7H8ClN3O4S2
 Molecular Weight
297.73
 Physical State 
White Powder 
 Solublity
Soluble in 0.1N HCL,  0.1N NaoH,  Methanol, Insoluble 
distilled H2O
 Therapeutic Category 
Diuretic,Antihypertensive Agent
 Mechanism Of Action  
Hydrochlorothiazide  inbbitis the reabsorbtion of Na and chloride 
at  the  beginning  of  the  distal  convoluted  tubule.  It  causes 
natriuretic  effect  mainly  by  decreasing  Na  and  chloride 
reabsorbtion in the cortical segment of the  ascending limb of the 
loop of  Henle  by inhibition of a specific Na+ Cl – Co- transporter.
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UV SPECTROPHOTOMETRIC SIMULTANEOUS EQUATION 
METHOD OF OLMESARTAN MEDOXOMIL AND 
HYDROCHLOROTHIAZIDE IN COMBINED TABLET DOSAGE 
FORM
PRINCIPLE:
If a sample contains two absorbing drugs (X and Y) each of which 
absorbs  at  the  λmax of  the  other.  It  may  be  possible  to  determine  the 
quantity of  both drugs by the technique of  simultaneous equation (or) 
Vierodt’s method.
Criteria for obtaining maximum precision, based upon absorbance 
ratios have been suggested that place limits on the relative concentrations 
of the component of the mixture.
A2 / A1 and ay2 / ay1
ax2 / ax1 A2 / A1
Where ax1, ax2 = Absorptivities of X at λ1 and λ2
ay1, ay2 = Absorptivities of X at λ1 and λ2
A1, A2 = Absorbances  of the diluted sample at λ1 and  λ2.
The ratio should lie outside the range of 0.1 – 2.0 for the precise 
determination of (Y and X) two drugs respectively.
These  criteria  are  satisfactory  only  when  the  λmax of  the  two 
components is reasonably dissimilar. The additional criteria includes that 
two components do not interact chemically, there by negating the initial 
assumption  that  the  total  absorbance  is  the  sum  of  the  individual 
absorbance’s.
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MATERIALS
Market Sample: OLMEZEST-H
                                  SUN PHARMA
Label claim: 
                    Olmesartan Medoxomil 20mg   
                     Hydrochlorothiazide 12.5mg 
Equipments Used:
 ATCO Balance
 SHIMADZU UV - & spectrophotometer double beam digital
UV-1700
Solvent Used:
 Methanol AR
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FIXATION OF VARIOUS PARAMETERS 
( Olmesartan Medoxomil) λmax
The wavelength at which maximum absorption takes is place called λmax
Determination of Absorption Maximum (λmax) for 
Olmesartan Medoxomil  
Procedure:
30  mg  of  authentic  Olmesartan  Medoxomil  sample  was  accurately 
weighed and transferred to 50ml volumetric flask and   methanol was 
added, dissolved and the volume was made upto 50ml with methanol.
5ml of this stock solution was pipetted out in to separate 100ml 
volumetric flask and the volume was made up to 100ml with methanol.
The absorbance of solution was measured against solvent blank in 
UV-region  of  200-400nm.  The  λmax was  found  to  be  215nm.  This 
spectrum of maximum absorbance is shown in graph.
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BEER’S LAW PLOT FOR OLMESARTAN MEDOXOMIL
  The  intensity  of  a  beam of  parallel  monochromatic  radiation 
decreases exponentially with the number of absorbing molecules. More 
simply it is stated that the absorbance is proportional to the concentration 
                        Log 10/IT =KC
Beer’s law plot was constructed by measuring the absorbance of various 
concentration of drug against solvent blank.
PROCEDURE
100mg  of  authentic  Olmesartan  Medoxomil  acid  sample  was 
accurately  weighed  and  transferred  to  100ml  volumetric  flask  and 
methanol was added, dissolved and the volume was made up to 100ml 
with methanol.
 From these aliquots of 0.5ml, 1ml, 1.5ml, 2ml, 2.5ml, 3ml, 3.5ml, 
4ml, 4.5ml, 5 ml was pipetted out in to separate 100ml volumetric flask. 
Then the volume was made upto 100ml with methanol. The absorbance 
of each solution was found out at 215nm against a reagent blank. The 
readings are presented in Table-1 and graph.
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Table – 1
DATA FOR BEER’S LAW PLOT FOR Olmesartan Medoxomil 
(Linearity)
S.No. Concentration μg/ml Absorption
1 5 0.1336
2 10 0.2672
3 15 0.4008
4 20 0.5344
5 25 0.668
6 30 8014
7 35 0.9352
8 40 1.0688
9 45 1.2004
10 50 1.336
Linearity Co -efficient (γ) = 0.999
Slope (m)  = 0.0267
 Intercept(c)                      = -0.00075
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DEVIATIONS FROM BEER’S LAW
A System is said to be obey Beer’s law where, a plot of concentration vs. 
absorbance gives a straight line by using a line of best fit, when a straight 
line is not obtained; the system is said to be deviated from Beer’s Law. 
For the drug Olmesartan Medoxomil maximum deviation was found in the 
Concentration range above 50μg/ml.  The readings are presented in
Table -2 and graph.
Table -2
DATA FOR DEVIATIONS FORM BEER’S LAW PLOT FOR 
OLMESARTAN MEDOXOMIL
S.No. Concentration μg/ml Absorbance
1. 5 0.1336
2. 10 0.2672
3. 15 0.4008
4. 20 0.5344
5. 25 0.668
6. 30 8014
7. 35 0.9352
8. 40 1.0688
9. 45 1.2004
10. 50 1.336
11 55 0.9357
12 60 0.9341
13 65 0.9293
14. 70 0.9210
Determination of Absorption Maximum (λmax) for Hydrochlorothiazide
Procedure:
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100mg  of  authentic Hydrochlorothiazide  sample  was  accurately 
weighed and transferred to 50ml volumetric flask and methanol was added, 
dissolved and the volume was made upto 50ml with methanol
5ml of this stock was pipetted out in to separate 100ml volumetric flask and 
the volume was made up to 100ml with methanol
The absorbance of solution was measured against solvent bank in UV-
region of 200-400 nm.  The λ max was found to be 226nm.  This spectrum of 
maximum absorbance is shown in graph.
BEER’S LAW PLOT FOR HYDROCHLOROTHIAZIDE
PROCEDURE
100mg  of  authentic  Hydrochlorothiazide   sample  was  accurately 
weighed and transferred to 100ml volumetric flask and methanol was added, 
dissolved and the volume was made up to 100ml with methanol. 
From these aliquots  of  0.5ml,  1ml,  1.5ml,  2ml,  2.5ml,  3ml,  3.5ml, 
4ml,  4.5ml,  5ml  was  pipetted  out  in  to  separate  100ml  volumetric  flask. 
Then the volume was made upto 100ml with methanol.  The absorbance of 
each solution was found out at 226 nm against a reagent blank.  The readings 
are presented in Table-3 and graph
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TABLE-3
DATA FOR BEER’S LAW PLOT FOR HYDROCHLOROTHIAZIDE
S.No. Concentration μg/ml Absorbance
1. 5 0.1809
2. 10 0.3618
3. 15 0.5427
4. 20 0.7236
5. 25 0.9045
6. 30 1.0854
7. 35 1.2663
8 40 1.4472
9 45 1.6281
10 50 1.809
Linearity coefficient γ = 0.9998
Slope(m)       = 0.03617
Intercept(c)                 =-0.00005
DEVIATIONS FROM BEER’S LAW
For  the  drug,  Hydrochlorothiazide  maximum  deviation  was 
found in the concentration range above 55μg/ml .The readings are presented 
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in Table –4 and graph.
Table – 4
Data for Deviations from Beer’s law plot for Hydrochlorothiazide 
hydrochloride
S.No. Concentration μg/ml Absorption
1 5 0.1809
2 10 0.3618
3 15 0.5427
4 20 0.7236
5 25 0.9045
6 30 1.0854
7 35 1.2663
8 40 1.4472
9 45 1.6281
10 50 1.809
11 55 1.253
12 60 1.251
13 65 1.250
14 70 1.248
   Preparation of olmesartan medoxomil standard solution
100mg  of  authentic  olmesartan  medoxomil  sample  is  accurately 
weighed and transferred to 100ml volumetric flask and methanol was added 
and shaken until  it  dissolves and the volume was made upto 100ml with 
methanol.
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From this 1ml was pipetted out in to separate 100ml volumetric flask 
and the volume was made up to 100ml with methanol.
Preparation of Hydrochlorothiazide standard solution 
100mg  of  authentic  Hydrochlorothiazide  sample  is  accurately 
weighed and transferred to 100ml volumetric flask and methanol was added 
and shaken until  it  dissolves and the volume was made upto 100ml with 
methanol.    
 From this 1ml was pipetted out in to separate 100ml volumetric flask 
and the volume was made up to 100ml with methanol.
The absorbance and absorptivity values are shown un Table-5a & 5b
Preparation of sample solution
Twenty tablets are weighed and average weight was calculated. The 
tablets  are  ground  to  a  fine  powder.  A  powder  equivalent  to  20mg  of 
olmesartan medoxomil  and 12.5mg of hydrochlorothiazide was accurately 
weighed and transferred to 50ml volumetric flask and methanol was added 
and shaken until  it  dissolves  and  the  volume was made  upto  50ml  with 
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methanol. This solution was filtered through whatmann filter paper. 
From this 1ml was pipetted out in to separate 100ml volumetric flask 
and the volume was made up to 100ml with methanol.
The  absorbance  of  each solution  was  found out  at  215nm (λmax of 
olmesartan medoxomil ) and 226nm (λmax of hydrochlorothiazide) against a 
reagent blank.
The analysis values are given in Table-6.
Calculation:
λ1 = 215nm (λmax of olmesartan medoxomil) λ2 =  226nm  (  λmax of 
hydrochlorothiazide )
X – olmesartan medoxomil
Y – hydrocholorothiazide
ax1 and ax2 – Absorptivities of olmesartan medoxomil  at  λ1 and λ2
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ay1 and ay2 – Absorptivities of  hydrocholorothiazide at λ1 and λ2 
Cx  and  Cy  –  Concentration  of  olmesartan  medoxomil   and 
hydrochlorothzide
  (Sample) in grams per 100ml
A1 and A2 – Absorbance of sample at λ1 and λ2    
Absorptivity (a) = A/bc = Absorbanceb x concentration of substance
Determination of Cx and Cy
Cx = A2ay1-A1ay2ax2 ay1- ax1 ay2
Cy = A1ax2-A2ax1ax2 ay1- ax1 ay2
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Table-5a
Absorbance values for standard and sample
Wavelength Olmesartan medoxomil Hydrochlorothiazide Sample
215
λ1
olmesartan 
medoxomil
0.1336 (X1) 0.1403 (Y1) 0.3535 (A1)
226
λ2
hydrochlorothiazide
0.1102(X2) 0.1809(Y2) 0.3560 (A2)
Table-5b
Absorptivity values for Olmesartan Medoxomil and 
Hydrochlorothiazide
Parameter
Absorptivity at  215nm Absorptivity at 226nm
Olmesartan 
Medoxomil
Hydro
Chlorothiazide
Olmesartan 
Medoxomil
Hydro
chlorothizide
*Mean ax1=267.2 ay1=280.6 ax2= 220.4 ay2=361.8
SD 0.3719 0.2455 0.3152 0.1220
*  Absorptivity values are the mean of six determinations. S.D. is standard 
deviation.   ax1  and  ax2  are  absorptivities  of  Olmesartan  Medoxomil  at 
215nm  and  226nm   respectively;  ay1  and  ay2  are  absorptivities  of 
hydrochlorothiazide at 215nm and 226nm respectively.
CRITERIA FOR OBTAINING MAXIMUM PRECISION
                               (A2 / A1)/ (ax2 / ax1)  and (ay2 / ay1)/ (A2 / A1) 
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was found to be 0.035 & 3.12  respectively. This ratio should lie outside the 
range 0.1-2.0 for the precise determination.
Table-6
Analysis data of tablet formulations
Parameters
UV-spectrophotometry
Olmesartan 
Medoxomil
Hydro
chlorothiazide
Label Claim 20mg 12.5mg
Amount found 19.9mg 12.35mg
*% Drug content 99.9 98.87
S.D. 0.1806 0.2097
% R.S.D 0.1790 0.2128
                   *value for % Drug content are mean of five estimations
RECOVERY STUDIES
To check  the  accuracy  of  the  developed  method  and  to  study  the 
interference of formulation additives, analytical recovery experiments were 
carried out by standard addition method at 80, 100 and 120% level. From the 
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total  amount  of  drug found the  percentage  recovery  was  calculated.  The 
results are reported in Table-7
Table 7
Recovery studies
Olmesartan Medoxomil
Range Amount 
found
*Recovery % R.S.D
80% 19.8mg 99.8% 0.1104
100% 19.9mg 99.9% 0.1192
120% 19.85mg 99.9% 0.0995
Hydrochlorothiazide 
Range Amount 
found
*Recovery % R.S.D
80% 12.4mg 98.9% 0.1011
100% 12.35mg 98.82% 0.1015
120% 12.35mg 99.0% 0.1929
*Recovery is the mean of three estimations
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DEVELOPMENT AND VALIDATION OF REVERSE PHASE 
HIGH PERFORMANCE LIQUID CHROMATOGRAPHY OF 
OLMESARTAN MEDOXOMIL   AND 
HYDROCHLOROTHIAZIDE
INSTRUMENTS 
 Shimadzu
 UV Visible SPD – 20A
 LC 20AT Isocratic
 Rheodyne
 C18.
Regents and Chemicals
 Acetonitrile
 HPLC grade water
 Buffer
 Methanol
REFERENCE STANDARDS :
Olmesartan Medoxomil and  hydrochlorothiazide 
These  two reference  standards  were  obtained as  gift  samples  from 
Dr.Ceeal  Lab,  Chennai    The  authenticity  and purity  of  the  sample  was 
certified by the same. 
Sample Tablet brand used : OLMEZEST – H
Dr. Ceeal Lab, Chennai 
Label claim : Olmesartan Medoxomil 20 mg 
Hydrochlorothiazide 12.5 mg
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METHOD DEVELOPMENT AND OPTIMIZATION :
SELECTION OF WAVELENGTH :
The   known  concentration  of  Olmesartan  Medoxomil  and 
Hydrochlorothiazide  acid  were  taken  and  dissolved  in  methanol.   The 
wavelength were tried at 250nm, 260nm, 270nm, and the Peaks of the drugs 
were showing fronting and tailing.  230 nm were selected for the analysis.
OPTIMIZATION OF CHROMATOGRAPHIC PARAMETERS 
(a) SELECTION OF MODE OF OPERATION:
As both the drugs were are polar in nature, a RP-HPLC method was 
proposed.
(b) SELECTION AND STANDARDISATION OF MOBILE PHASE :
OLMEZEST - H   is combination of Olmesartan Medoxomil 20 mg 
and hydrochlorothiazide 12.5 mg.  The method development of Olmesartan 
Medoxomil   and hydrochlorothiazide required adequate resolution of two 
drug peaks in the chromatogram.
DIFFERENT COMBINATIONS OF BUFFER AND SOLVENTS:
Buffer Sodium di hydrogen phosphate and acetonitrile (70:30)
Buffer  Sodium dihydrogen phosphate  and acetonitrile (50:50)
Buffer  (Sodium  dihydrogen  phosphate)  and  acetonitrile  (50:50) 
methanol:acetonitrile (50:30:20)
Peaks of Olmesartan Medoxomil   and Hydrochlorothiazide were well 
resolved  with  solvent  system.  Buffer  Sodium  di  hydrogen  phosphate  : 
methanol: acetonitrile (60:20:20) and it is shown in figure-1.
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SELECTION OF FLOW RATE :
The Flow rate for Olmesartan Medoxomil   and Hydrochlorothiazide 
were tried with 0.4ml, 0.5ml, and 0.7ml and the peaks of the drugs were 
showing fronting and tailing with 0.4ml and 0.7ml respectively and finally 
1 ml per minute was selected for the analysis.
PREPARATION OF BUFFER SOLUTION :
Buffer  solution  was  prepared  by  using  1.3609gm  of  sodium  di 
hydrogen of HPLC grade water, filtered through 0.45µ nylon membrane and 
degassed.
PREPARATION OF MOBILE PHASE :
Mix the Buffer, methanol: and acetonitrile in the ratio of 60:20:20 and 
degass it.  Filtered through 0.45µ membrane.
DILUENTS
Mobile phase is used as diluents.
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DETERMINATION OF RETENTION TIME :
(A) PREPARATION  OF  STANDARD  SOLUTION  OF 
OLMESARTAN MEDOXOMIL 
Accurately 0.200g Olmesartan Medoxomil was taken in a 100ml 
volumetric flask and the volume was adjusted to 100ml with mobile 
phase.  5ml  was  taken in  a  separate  50ml  volumetric  flask and the 
volume was adjusted to 50 ml with mobile phase to get concentration 
of 200  µg/ml of Olmesartan Medoxomil.  20µl of this solution was 
injected and chromatogram was obtained and it is in shown Figure-2.
(B)  PREPARATION  OF  STANDARD  SOLUTION  OF 
HYDROCHLOROTHIAZIDE. 
Accurately  0.125g  of  hydrochlorothiazide  was  taken  in  a  100ml 
volumetric flask and the volume was adjusted to 100ml with mobile phase. 
5 ml was taken in a separate volumetric flask of 50ml and the volume was 
adjusted to 50ml with mobile phase to get a concentration of 125  µg/ml. 
20 µl of this solution was injected and the chromatogram was recorded and 
shown in Figure-3.
(C) PREPARATION OF MIXED STANDARD SOLUTION :
0. 200g  of Olmesartan Medoxomil and 0.125g of hydrochlorothiazide 
was transferred into a 100ml dried volumetric flask.  The compounds were 
first  dissolved  in  20ml  of  mobile  phase  and  it  was  sonicated.  Then  the 
volume was adjusted to 100ml with mobile phase.  From the stock solution 
102
5ml was transferred to a 50ml volumetric flask and the volume was adjusted 
to 50ml with mobile phase to get a concentration of 200µg/ml of Olmesartan 
Medoxomil  and 125  µg/ml of hydrochlorothiazide.    20µ if the resulting 
solution was injected and chromatogram was recorded shown in Figure-4.
FIXED CHROMATOGRAPHIC CONDITIONS :
INSTRUMENT : Shimadzu Prominence model
LC 20 AT Isocratic
COLUMN : CN18
WAVELENGTH : 230nm
TEMPERATURE : Ambient temperature
FLOW RATE : 1 ml / mit
INJECTION VOLUME : 20µl
MOBILE PHASE : Buffer (Sodium dihydrogen phosphate
Methanol and acetonitrile 60.20:20
RETENTION TIME : 4.383 for Olmesartan Medoxomil   for 3.150 
for hydrochlorothiazide
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QUANTITATIVE  DETERMINATION  OF  THE  DRUGS  OF  THE 
DRUGS BY USING THE DEVELOPED METHOD
Sample : Olmesartan Medoxomil 
Hydrochlorothiazide 
Label Claim : Olmesartan Medoxomil 20mg
Hydrochlorothiazide  12.5 mg
METHOD :
Twenty tablets were weighed and powdered.  Average weight 593.2g 
of  sample  tablet  OLMEZEST  -  H  (equivalent  20  mg  of  Olmesartan 
Medoxomil   and  12.5 mg of  hydrochlorothiazide was  taken into 100ml 
dried  volumetric  flask.   The  powder  was  first  dissolved in  20ml  mobile 
phase  and sonicated  and finally  the  volume was adjusted  to  100ml  with 
mobile phase.  From this solution 5ml was transferred to 50ml volumetric 
flask  and  volume  was  adjusted  to  50ml  with  mobile  phase  to  get  a 
concentration  of  200µg/ml  of  Olmesartan  Medoxomil   and  125  µ/ml  of 
hydrochlorothiazide.   20µl  of  the  solution  was  injected  and  the 
chromatogram obtained is shown in Figure 5.
The  amount  of  Olmesartan  Medoxomil   and  hydrochlorothiazide 
present in the tablet formulation was calculated by comparing the peak area 
of the standard and reports are given in Table-8.
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Amount of drug present in the tablet:
              Sample area          Standard dilution              Potency
           ____________ x     _______________     x  _________ x Average weight
             Standard Area        Sample dilution                    100
                                          Amount present             
Percentage purity =         ____________  x 100
                                           Label claim
Table – 8
Quantitative  Estimation
S.No. Brand 
Name
Content Label 
Claim 
(mg)
Peak 
area
Amount 
present 
(mg)
Percent 
Purity % 
w/v
1. Olmezest
-H
Olmesartan 
Medoxomil
20 mg 2346.12
5
20.08 
mg
100.40 %
Hydrochloro
Thiazide 
12.5 
mg
4563.53
9
12.49 
mg
99.9 %
Acceptance critearia : 98-102% w/v
Assay for Olmesartan Medoxomil
Amount Present =
            2346.125             200                99.85                
            ________      x   ____     x     _________  x    144.9 =  20.08 mg
            2333.090            1449                100              
Percentage Purity =  20.08/20  x 100 =  100.40
    
Assay for Hydrochlorothiazide 
Amount Present =  4563.539    125 99.93
_________ x ____  x  _____  x   144.9 =12.49 mg
4560.786  1449 100
  Percentage  Purity =   12.49  / 12.5 x  100 = 99.9 %
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VALIDATION
Validation  of  an  analytical  method  is  a  process  to  establish  by 
laboratory studies that the performance characteristics of the method meet 
the  requirements  for  the  intended  analytical  application.   Performance 
characteristics are expressed in terms of analytical parameters.
Design of experiment :
 Specificity
 Linearity and range
 Limit of quantification
 Limit of detection
 Accuracy
 Precision
o System precision
o Method precision
 Robustness
 Ruggedness
 System suitability studies
o Resolution
o Number of theoretical plates
o The tailing factor.
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SPECIFICITY 
The specificity of an analytical methods is  ability to measure accurately and 
specifically the analytes in the presence of compounds that may e expected 
to be present in the sample matrix.
Determination 
The specificity of the analytical methods was determined by injecting the 
placebo solution under the same experimental conditions as the assay.
Preparation of placebo 
Placebo is prepared by mixing all the excipients  without active ingredients 
Procedure 
 225 mg placebo was accurately weighted and transferred into 25 ml 
volumetric flask  and the volume as made to 25 ml with the mobile 
phase.  The solution was filtered through Millipore filter  paper  and 
degassed. 20 µl of this solution was injected and  chromatogram was 
recorded and shown in figure-6.
 200 mg olmesartan medoxomil and 125 mg hydrochlorothiazide were 
weighed and  transferred into a 100 ml volumetric flask and volume 
was  adjusted  to  100  ml  with  mobile  phase.  Further  5  ml  of  the 
solution was taken and the volume was made upto 50 ml  to get  a 
concentration  of  200/µg/ml   olmesartan  medoxomil   &  125µg/ml 
hydrochlorothiazide to this solution 90 mg of placebo was added and 
it was sonicated, filtered through a Millipore filter paper 20 up of this 
solution  was  injected,  chromatogram  was  recorded  and  shown  in 
Figure-7  the report are shown in Table 9 & 10.
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TABLE – 9
SPECIFICITY FOR OLMESARTAN MEDOXOMIL
S.No Sample Area Obtained
1 Standard 2332.090
2 Standard + Placebo 2330.642
3 Placebo 0
TABLE – 10
SPECIFICITY FOR HYDROCHLOROTHIAZIDE
S.No Sample Area Obtained
1 Standard 4560.786
2 Standard + Placebo 4561.253
3 Placebo 0
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LINEARITY  AND RANGE
Linearity of an analytical method is its ability to elicit test result that are 
directly  promotional  to  the  concentration  of  analyte  in  samples  within  a 
given range.
Determination
The  linearity  of  the  analytical  method  was  determined  by  mathematical 
treatment  of  test  result  obtained  by  analysis  of  sample  with  analyst 
concentration across the claimed range. Area was plotted graphically as a 
function of analyst concentration. Percentage curve fitting was calculated.
METHOD 
Preparation of mixed standard stock solution 
Accurately  weighted  200   mg  olmesartan  medoxomil   and  125   mg 
hydrochlorothiazide were transferred in to the 100 ml of standard flask and it 
was dissolved with mobile phase and the volume was made upto 100ml with 
mobile phase. From the resulting solution 4,4.5, 5, 5.5 6 ml were transferred 
into 5 different 50 ml volumetric flask. The volume was made with mobile 
phase  to  get  a  final  concentration  of   160,  180,  200,220,  240µg/ml  of 
olmesartan   medoxomil  100,  112.5,  125,  137.5,  150µg/ml  of 
hydrochlorothiazide.  20  µl   of  the  resulting  solution  was  injected  and 
chromatogram was recorded. 
The  chromatograms  of  Olmesartan  Medoxomil  and 
hydrochlorothiazide  are shown in figure 8-12.    
 Acceptance Criteria 
Correlation coefficient should not be less than 0.99
The  linearity  datas  and  analytical  performance  parameters  of  olmesartan 
medoxomil  and  hydrochlorothiazide  are  shown  in  Table  11-13  and 
calibration curve are shown in graph. 
109
TABLE – 11
    LINEARITY DATA  
OLMESARTAN MEDOXOMIL
S.No Concentration µg/ml Peak Area 
1 160 1840.700
2 180 2109.02
3 200 2328.729
4 220 2556.345
5 240 2812.535
Table – 12
HYDROCHLOROTHIAZIDE
S.No Concentration µg/ml Peak Area 
1 100.0 3654.119
2 112.5 4104.276
3 125.0 4555.297
4 137.5 5015.889
5 150.0 5472.902
TABLE – 13
ANALYTICAL PERFORMANCE PARAMETERS
S.No Drug name Linear 
dynamic 
range  (µg/
ml )
Correlation 
coefficient
Slope Intercept 
1 Olmesartan 
Medoxomil
160-240 0.9994 11.9514
3
-60.6784
2 Hydrochlorothiazid
e
100-150 0.9999 36.3934 11.3176
110
ACCURACY 
The accuracy of an analytical method  is the closeness of the results obtained 
by  that  method  to  the  true  value.  Accuracy  may  often  be  expressed  as 
percent recovery by the assay of known added amount of analyte.
Determination 
The  accuracy  of  the  analytical  method  was  determined  by  applying  the 
method to the analysed samples to which known amounts of analyte had 
been  added.  The  accuracy  was  calculated  from  the  test  results  as  the 
percentage of analyte recovered by the assay.
Acceptance criteria :
Percentage recovery should be within 98-102 % 
PROCEDURE 
Mixed standard stock solution 2 ml and sample  stock solution 2 ml were 
mixed together in 50 ml volumetric flask and the volume was made upto 
50ml with mobile phase to get 80 % range. Similarly 100 % and 120 % 
range  was  prepared  20µl  of  this  solution  was  injected  three  times  and 
chromatograms were shown in Fig. 13 to 21 and values in table 14 and 15.
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TABLE -14
RECOVERY STUDY OF OLMESARTAN MEDOXOMIL
S.No Range Area 
Obtained 
Amount 
Recovered 
(mg) 
% Recovery 
1
80 %
1851.636 19.81 99.05
1851.698 19.81 99.05
1850.730 19.80 99.00
2
100 %
2317.664 19.83 99.18
2318.012 19.84 99.20
2317.687 19.83 99.19
3
120 %
2807.483 20.02 100.12
2806.632 20.01 100.09
2807.455 20.02 100.12
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TABLE – 15
RECOVERY STUDY HYDROCHLOROTHIAZIDE 
S.No Range Area 
Obtained 
Amount 
Recovered 
(mg) 
% Recovery 
1
80 %
3671.848 12.55 100.46
3671.863 12.56 100.46
3670.995 12.56 100.44
2
100 %
4549.086 12.45 99.60
4549.099 12.45 99.70
4549.102 12.45 99.60
3 120 % 5438.741 12.41 99.30
5439.231 12.41 99.31
5438.929 12.41 99.30
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PRECISION
Precision  of  an  analytical  method  is  the  degree  of  agreement  among 
individual test results when the procedure is applied repeatedly to multiple 
sampling of a homogenous sample. Precision of analytical method is usually 
expressed as the standard deviation and relative standard deviation.
Determination : 
The  precision  of  the  analytical  method  was  determined  by  assaying 
sufficient number of sample and relative standard deviation was calculated.
The precision of  the instrument  was determined by assaying the samples 
consecutively,  number  of  time  and  relative  standard  deviation  was 
calculated.
Acceptance Criteria 
The relative standard  deviation should be with in 2 %
SYSTEM PRECISION 
Procedure 
Accurately  weighed  200  mg  olmesartan  medoxomil   and  125  mg  of 
hydrochlorothiazide  acid were  transferred into 100 ml standard flask and it 
was dissolved with mobile phase.  From the resulting solution 50 ml  was 
transferred  into  50  ml  volumetric  flask.  The  volume  was  made  up  with 
mobile phase to 50 ml.
The system precision was evaluated by measuring 6 successive injection of 
20µl  of  standard  solution.  The  peak  response  were  measured  from  the 
chromatogram shown in  figure 22-27 and system precision data area shown 
in table 16 & 17..
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Method Precision 
Procedure 
Twenty  tables  were  weighted  and  powdered.  Average  weight  144.9  of 
sample tablet  OLMEZST-H (equivalent  to 200mg olmesartan medoxomil 
and  1250 mg of hydrochlorothiazide was taken into 100 ml dried volumetric 
flask. The power was first dissolved in 20ml of mobile phase and sonicated 
and finally the volume was adjusted to 100 ml with mobile phase. From this 
solution 5ml transferred to 50 ml volumetric flask and volume was adjusted 
to  50  ml  with  mobile  phase  to  get  a   concentration  of  200  µg/ml  of 
olmesartan medoxomil and 125  µg/ ml of  hydrochlorothiazide. 20µl of the 
solution  was  injected  and  the  chromatogram  obtained  is  shown  in 
Figure 28-33 and method precision data are shown in table 18-20.       
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TABLE – 16
SYSTEM PRECISION DATA
S.No Area of Olemesartan medoxomil Area of 
Hydrochlorothiazide 
1 2330.464 4560.789
2 2350.522 4576.226
3 2324.136 4572.686
4 2316.563 4581.903
5 2324.821 4571.016
6 2326.064 4553.828
Mean 2328.761 4569.408
S.D. 11.5708 10.3234
% 
RSD
0.4968 0.2259
Table -17
Relative 
standard 
deviation 
Olmesartan 
Medoxomil 
Hydrochlorothiazid
e 
Acceptance 
Criteria 
0.496 0.2259 2 %
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Table – 18 Method Precision of  Olemesartan Medoxomile 
S.No Area Obtained Amount Recovered 
in ( mg)
Purity % w/v
1 2338.738 20.04 100.20
2 2347.046 19.94 99.70
3 2356.955 20.25 101.20
4 2349.124 20.25 101.25
5 2357.832 20.26 101.26
6 2358.983 20.25 101.26
MEAN 100.82
STANDARD DEVIATION 7.9269
RELATIVE STAND DEVIATION 0.3371
Table – 19 Method Precision of  hydrochlorothiazide  
S.No Area Obtained Amount Recovered 
In (mg)
Purity % w/v
1 4563.542 12.49 99.99
2 4584.705 12.51 100.11
3 4547.645 12.42 99.38
4 4584.653 12.49 99.98
5 4573.801 12.49 99.99
6 4556.599 12.49 99.99
MEAN 99.90
STANDARD DEVIATION 15.1839
RELATIVE STAND DEVIATION 0.3323
Table – 20 Method Precision report for Olmesartan Mexoxomil and 
Hydrochlorothiazide 
Relative  standard 
deviation 
Olmesartan 
Medoxomil 
Hydrochlorothiazide Acceptance 
Criteria 
0.3371 0.3223 2 %
LIMIT OF DETECTION (LOD )
It is the lowest amount of analyte in a sample that can be detected  but not 
necessary  quantities  as  an   exact  value  under  the  stated,  experimental 
conditions. The detection limit is usually expressed as the concentration of 
analyte.
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It is given  by
LOD = 3.3 xσ
--------
m 
σ = standard deviation of the response 
m =slope of the calibration curve 
      TABLE – 21
LIMIT OF DETECTION 
DRUG STANDARD 
DEVIATION 
SLOPE L.O.D µg/ ml
Olmesartan 
Medoxomil
11.5708 11.95143 3.194
Hydrochlor 
thiazide
10.3234 36.393432 0.93608
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LIMIT OF  QUANTITATION
The Quantitation limit of an analytical procedure is the lowest amount of 
analytic which can be quantitatively determined with suitable precision and 
Accuracy.
It is given by
L.O.Q = 10x σ
   ------
    m
σ= Standard deviation of the response 
m= slope of the calibration  curve 
TABLE – 22
LIMIT OF QUANTITATION 
DRUG STANDARD 
DEVIATION 
SLOPE L.O.Qµg / ml
Olmesartan 
Medoxomil
11.5708 11.95143 9.6815
Hydrochlorothiazid
e 
10.3234 36.3934 2.8366
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RUGGEDNESS
The Ruggedness of an analytical method is degree of reproducibility of test 
result obtained by the analysis of the same sample under a variety of normal 
test  condition,  such  as  different  laboratories,  different  analyst,  different 
assay temperature, different days etc.
Ruggedness is normally expressed as the lack of influence of test result of 
operations and environmental variables of the analytical method.
 
Determination :
The  ruggedness  of  an  analytical  method  was  determined  by  analysis  of 
aliquots from homogenous lots by different analysis using operations and 
environmental  conditions  that  may  different  but  were  still  with  in  the 
specified parameters of the assay. The degree of reproducibility of test result 
was  then  determined  as  a  function  of  the  assay  variables.  This 
reproducibility  was then determined as  a function of  the assay  variables. 
This  reproducibility  was  assayed  under  normal  conditions  to  obtain  a 
measure of the ruggedness of analytical method.
The assay  olmesartan medoxomil  and hydrochlorothiazide were performed 
in different conditions  like different analyst on different days.
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METHOD 
The standard  and sample solutions were prepared by different analysts on 
different days and the resulting solution were injected and chromatograms 
are recorded and shown in  Figure 35-42 and ruggedness of the method and 
report of olmesartan medoxomil and  hydrochlorothiazide  acid or shown in 
Table 26.
Table -23
RUGGEDNESS
Analyst Date Amount Found % purity
Olmesartan 
Medoxomil 
Hydrochlorothiazid
e 
Olmesartan 
Medoxomil 
Hydrochlorothiazide 
I 19 
Nov 
2008
20.251 mg 12.498 mg 101.27 99.98
II 20 
Nov 
2008
20.254 mg 12.494 mg 101.27 99.95
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ROBUSTNESS
Robustness of an  analytical method is measure of its capacity to remain 
unaffected  by  small  but  deliberate  variations  in  method  parameters  and 
provides an indication of its reliability during  normal usage.
Determination 
The  robustness  of  an  analytical  method  was  determined  by  analysis  of 
aliquots from homogenous lots by different  physical parameters that may 
differ  but  were  within  the  specified  parameter  of  the  assay  for  example 
change in physical parameters like flow rate and lambda max.
Method 
Standard  solution preparation 
200  mg  olmesartan  medoxomil  and  125  mg  hydrochlorothiazide  were 
transferred into a 100 ml volumetric flask, volume was adjusted to 100 ml 
with mobile phase. Further 5 ml of the solution was taken and the volume 
was made upto 50 ml to get a concentration of 200  µg/ml of olmesartan 
medoxomil  and 250 µg/ml of hydrochlorothiazide. 
Sample preparation 
Twenty tablets were weighted and  powered. Average weight  144.9 g of 
sample  tablet OLMEZEST-H ( equivalent to 200 mg olmesartan medoxomil 
125 mg hydrochlorothiazide) was taken into 100 ml dried volumetric flask. 
The powder was first dissolved in 20 ml of mobile phase. From this solution 
5 ml was transferred in to 50 ml volumetric flask and volume was adjusted 
to  100  ml  with  mobile  phase.  20µl  of  this  solution  was  injected  and 
individual chromatograms were recorded and they are in figure 38-45 and 
datas are shown in Table 24-31.   
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TABLE 24
Chromatographic conditions  : - change in flow rate 0.8 ml/ min
Change in flow rate 0.8 ml / min
Column CN
Wave length 230 nm
Temperature Ambient  250.c
Injection volume 20 µl
TABLE 25
Change in flow rate  0.8 ml/ min
S.No Drug standard 
area 
sample area % Purity 
w/v
1 Olmesartan 
Medoxomil 
2162.835 2195.655 101.36
2 Hydrochlorothiazid
e 
4144.16 4146.914 99.99
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TABLE -26
Chromatographic condition :- change in flow rate (1.2 ml/ min )
Change in flow rate 1.2 ml / min
Column CN
Wave length 230 nm
Temperature Ambient  25oc
Injection volume 20 µl
TABLE 27
Change in flow rate 1.2ml/ min
S.No Drug  Standard 
sample 
sample area % Purity 
w/v
1 Olmesartan 
Medoxomil 
1615.951 1648.766 101.87
2 Hydrochlorothiazid
e 
2516.911 2919.671 100.02
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TABLE -28
Chromatographic condition :- change in Lambda Max 232 nm 
Column CN
Wave length 230 nm
Temperature Ambient 25oc
Injection Volume 20 µl
Flow rate 1 ml/min
TABLE 29
Change in flow rate 232 nm
S.No Drug standard 
area 
sample area % Purity 
w/v
1 Olmesartan 
Medoxomil 
2220.564 2253.385 101.36
2 Hydrochlorothiazid
e 
4422.845 4425.600 99.99
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TABLE -30
Chromatographic conditions : - Change in Lambda Max 228  nm
Column CN
Wave length 230 nm
Temperature Ambient 250c
Injection Volume 20 µl
Flow rate 1 ml/ min
TABLE 31
Change in flow rate 228 nm
S.No Drug standard 
area
sample area % Purity 
w/v
1 Olmesartan 
Medoxomil 
2414.815 2447.130 101.21
2 Hydrochlorothiazid
e 
4648.815 4649.571 99.94
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SYSTEM SUITABILITY PARAMETERS 
System suitability testing is an integral part of many analytical procedures. 
The  test  based  on the  concept  that  the  equipment,  electronics,  analytical 
operation and sample to be analysed constitute an integral system that can be 
evaluated as such. System suitability test parameters to be established for a 
particulars procedure depend on the type of procedure being validated.
Method 
A  solution  of  200µg/ml  of  Olmesartan  medoxomil  and   125µg/ml 
hydrochlorothiazide were prepared by diluting with mobile phase and same 
was injected and a chromatogram was recorded and they are shown in figure 
59 and system suitability report are shown in the following.
TABLE – 32
SYSTEM SUITABILITY PARAMETERS
S.No Parameters Olmesartan 
Medoxomil  
Hydrochlorothiazide 
1 Theoretical plates 8797 4280
2 Tailing Factor 1.444 1.783
3 Resolution 6.499
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RESULTS AND DISCUSSION
Drotaverine hydrochloride and mefenamic acid 
UV  Spectrophotometery  and  reverse  phase  high  performance  liquid 
chromatography  were  developed for  analyzing Drotaverine  hydrochloride 
and mefenamic acid  in combined tablet  dosage form.
For UV spectrophotometry linearity was obtained in the concentration  range 
of   5  to  50  µg/ml  for  both  drugs.  In  simultaneous  equation  method  the 
%  drug  content  was   found  to  be  99.95  %  98.80  %  for  Drotaverine 
hydrochloride and mefenamic acid. Recovery experiments were performed 
and it  was within 98-102 % and showed  < 2 %  RSD which is  highly 
precises and accurate for the proposed methods.
In HPLC method, HPLC conditions were optimized to obtain an adequate 
separation of eluted compounds. Initially various mobile phase were tried, to 
separate drugs.  Mobile  phase and flow rate selection was based on peak 
parameters ( height, tailing, theoretical plates, etc). The system with buffer 
(  potassium di  hydrogen phosphate  )  :  methanol  :  Acetonitrile  (50:15:35 
v/v) with 1.5  ml/ / min flow rate is  quite robust. The optimum wavelength 
for detection was 240 nm at which better detector response for drugs was 
obtained.  The  average  retention  times  Drotaverine  hydrochloride  and 
mefenamic acid is 6.4  min and 3.0 min respectively. 
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According  to  USP  system  suitability  test  are  an  integral  part  of 
chromatographic  method. They are used to verify the reproducibility of the 
chromatographic  system.  To ascertain  its  effectiveness,  system suitability 
tests were carried out on freshly prepared stock solution. 
The  calibration  curve  was  found  to  be  linear  for  both  Drotaverine 
hydrochloride and mefenamic acid .  The percentage purity was 100.20  % 
and  100.05  %  for  Drotaverine  hydrochloride  and  mefenamic  acid 
respectively.
The mean recoveries were found to be in the range of 98 % to 102 %.   
Limit of detection for Drotaverine hydrochloride and mefenamic acid  was 
found to be 0.00076519µg/ml and 0.003796µg/ml respectively.
Limit  of quantitation for   Drotaverine hydrochloride and mefenamic acid 
was found to be 0.002318µg/ml and 0.011505µg/ml respectively. 
Robustness  of  the  proposed  method  was  determined  by  changing  the 
wavelength and flow rate.
Ruggedness  of  proposed  method  was  determined  by  analysis  of  aliquots 
from homogenous slot by different analyst in different days using similar 
operation  environmental conditions. The results were within 98-102 %.
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Olmesartan Medoxomil and hydrochlorothiazide  
UV  Spectrophotometery  and  reverse  phase  high  performance  liquid 
chromatography were developed for analyzing Olmesartan Medoxomil and 
hydrochlorothiazide   in combined tablet  dosage form.
For UV spectrophotometry linearity was obtained in the concentration  range 
of   5  to  50  µg/ml  for  both  drugs.  In  simultaneous  equation  method  the 
% drug content was  found to be 99.99 % and  98.82 % for Olmesartan 
Medoxomil and hydrochlorothiazide. Recovery experiments were performed 
and it  was within 98-102 % and showed  < 2 %  RSD which is  highly 
precises and accurate for the proposed methods.
In HPLC method, HPLC conditions were optimized to obtain an adequate 
separation of eluted compounds. Initially various mobile phase were tried, to 
separate drugs.  Mobile  phase and flow rate selection was based on peak 
parameters ( height, tailing, theoretical plates, etc). The system with buffer 
(sodium di hydrogen phosphate ) : methanol : Acetonitrile (60:20:20  v/v) 
with  1  ml/min  flow rate  is   quite  robust.  The  optimum wavelength  for 
detection  was  230  nm  at  which  better  detector  response  for  drugs  was 
obtained.  The  average  retention  times  Olmesartan  Medoxomil  and 
hydrochlorothiazide is 4.383  min and 3.150 min respectively. 
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According  to  USP  system  suitability  test  are  an  integral  part  of 
chromatographic  method. They are used to verify the reproducibility of the 
chromatographic  system.  To ascertain  its  effectiveness,  system suitability 
tests were carried out on freshly prepared stock solution. 
The  calibration  curve  was  found  to  be  linear  for  both  Olmesartan 
Medoxomil and hydrochlorothiazide.  The percentage purity was 100.40  % 
and  99.9  %  for  Olmesartan  Medoxomil  and  hydrochlorothiazide 
respectively.
The mean recoveries were found to be in the range of 98 % to 102 % .
Limit of detection for Olmesartan Medoxomil and hydrochlorothiazide  was 
found to be 3.194µg/ml and 0.93608µg/ml respectively.
Limit of quantitation for   Olmesartan Medoxomil and hydrochlorothiazide 
was found to be 9.6815µg/ml and 2.8360µg/ml respectively .
Robustness  of  the  proposed  method  was  determined  by  changing   the 
wavelength and flow rate.
Ruggedness  of  proposed  method  was  determined  by  analysis  of  aliquots 
from homogenous slot by different analyst in different days using similar 
operation  environmental conditions. The results were within 98-102 %.
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SUMMARY AND CONCLUSION
Drotaverine hydrochloride and Mefenamic  aid in combined tablet dosage 
form  analyzed  by  UV  –  spectrophotometric  simultaneous  equation  and 
Reverse phase high performance liquid chromatography.
On comparing these methods Reverse phase high performance liquid 
chromatography  was  found  to  be  more  precise,  accurate,  rugged, 
robust,simple, and rapid than UV spectrophotometric method.
Olmesartan medoxomil  and hydrochlorothiazide in  combined tablet 
dosage  from  was  analyzed  by  UV  –  spectrophotometric  simultaneous 
equation  method  and  Reverse  phase  high  performance  liquid 
chromatography.
On  comparing  these  methods  Reverse  phase  high  performance 
chromatography was found to  be  more precise,  accurate,  rugged robust, 
simple and rapid than spectrometric method.
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